WO2006008639A1 - Combination treatment for non-hematologic malignancies using an anti-igf-1r antibody - Google Patents

Combination treatment for non-hematologic malignancies using an anti-igf-1r antibody Download PDF

Info

Publication number
WO2006008639A1
WO2006008639A1 PCT/IB2005/002096 IB2005002096W WO2006008639A1 WO 2006008639 A1 WO2006008639 A1 WO 2006008639A1 IB 2005002096 W IB2005002096 W IB 2005002096W WO 2006008639 A1 WO2006008639 A1 WO 2006008639A1
Authority
WO
WIPO (PCT)
Prior art keywords
antibody
igf
cdr
amino acid
group
Prior art date
Application number
PCT/IB2005/002096
Other languages
French (fr)
Other versions
WO2006008639A8 (en
Inventor
Antonio Gualberto
Bruce David Cohen
Carrie Lynn Melvin
Maria Luisa Roberts
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35058695&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2006008639(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to NZ552091A priority Critical patent/NZ552091A/en
Priority to AU2005264063A priority patent/AU2005264063B2/en
Priority to JP2007520919A priority patent/JP2008506681A/en
Priority to CA002573821A priority patent/CA2573821A1/en
Priority to EP05757374A priority patent/EP1802341A1/en
Priority to BRPI0513200-2A priority patent/BRPI0513200A/en
Priority to CN2005800240273A priority patent/CN101014365B/en
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Priority to MX2007000610A priority patent/MX2007000610A/en
Publication of WO2006008639A1 publication Critical patent/WO2006008639A1/en
Priority to IL180422A priority patent/IL180422A0/en
Priority to NO20070702A priority patent/NO20070702L/en
Publication of WO2006008639A8 publication Critical patent/WO2006008639A8/en
Priority to HK07110312.3A priority patent/HK1105151A1/en
Priority to AU2009210360A priority patent/AU2009210360B2/en
Priority to IL210401A priority patent/IL210401A0/en
Priority to IL210400A priority patent/IL210400A0/en
Priority to IL210399A priority patent/IL210399A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • the present invention relates to a method of treatment for non-hematologic malignancies comprising the administration of anti-insulin-like growth factor I receptor (IGF- 1 R) antibodies, in conjunction with other therapeutic agents such as chemotherapeutic agents and hormonal therapy.
  • IGF- 1 R anti-insulin-like growth factor I receptor
  • IGF insulin-like growth factor
  • IGF-1 insulin-like growth factor-1
  • IGF-1 stimulates cell differentiation and cell proliferation, and is required by most mammalian cell types for sustained proliferation. These cell types include, among others, human diploid fibroblasts, epithelial cells, smooth muscle cells, T lymphocytes, neural cells, myeloid cells, chondrocytes, osteoblasts and bone marrow stem cells.
  • the first step in the transduction pathway leading to IGF-1 -stimulated cellular proliferation or differentiation is binding of IGF-1 or IGF-2 (or insulin at supraphysiological concentrations) to the IGF-1 receptor.
  • the IGF-1 receptor (IGF-1 R) is composed of two types of subunits: an alpha subunit (a 130-135 kD protein that is entirely extracellular and functions in ligand binding) and a beta subunit (a 95-kD transmembrane protein, with transmembrane and cytoplasmic domains).
  • IGF binding proteins IGFBPs
  • IGFBPs have growth inhibiting effects by, at least in part, competitively binding IGFs and preventing their association with IGF-1 F.
  • the interactions between IGF-1 , IGF-2, IGF1 R, and IGFBPs affect many physiological and pathological processes such as development, growth and metabolic regulation.
  • IGF-1 and/or IGF-1 R are elevated in tumors of lung (Kaiser et al.,
  • IGF-1 appears to be an autocrine stimulator of human gliomas (Sandberg-Nordqvist et al., Cancer Res. 53: 2475-2478, 1993), while IGF-1 stimulated the growth of fibrosarcomas that overexpressed IGF-1R (Butler et al., Cancer Res. 58: 3021-27, 1998).
  • individuals with "high normal” levels of IGF-1 have an increased risk of common cancers compared to individuals with IGF-1 levels in the "low normal” range (Rosen et al., Trends Endocrinol. Metab. 10: 136-41 , 1999).
  • IGF-1/IGF-1 receptor interaction plays in the growth of a variety of human tumors, see Macaulay, Br. J. Cancer, 65: 311-320, 1992.
  • Docetaxel one of a group of drugs called “taxanes,” which are derived from the bark and needles of yew trees, is the first anticancer agent to show a significantly higher response rate than doxorubicin, a very active agent and widely used chemotherapy in the first-line treatment of metastatic breast cancer.
  • Docetaxel also is the first chemotherapy drug as a single agent to demonstrate increased survival among patients with advanced breast cancer compared to the combination of mitomycin C and vinblastine, a commonly used regimen in this patient population. Median time to progression and time to treatment failure were significantly longer for docetaxel than for mitomycin C in combination with vinblastine, and the one-year survival rate significantly greater. Promising results have also been recorded for docetaxel in other human malignancies, such as ovarian, lung, head and neck, gastric and pancreatic cancers.
  • Paclitaxel also a taxane, binds to microtubules and prevents their molecular disassembly, thereby inhibiting mitosis (cell division). With the spindle still in place the cell cannot divide into daughter cells. Paclitaxel is most effective against ovarian carcinomas and advanced breast carcinomas.
  • Hormonal therapy can be very effective in lowering the risk of recurrence for women with hormone-receptor-positive breast cancer.
  • Tamoxifen is the hormonal therapy that has been around the longest — nearly 30 years. It blocks the effect of estrogen on breast cancer cells, keeping the cells from growing. Tamoxifen can reduce recurrence by 40-50% in post ⁇ menopausal women, and by 30-50% in pre-menopausal women. It also lowers the risk of a new breast cancer developing in the unaffected breast, and can slow down the progression of advanced disease.
  • aromatase inhibitors have been used as hormonal therapy. This type of therapy is recommended only for postmenopausal women with hormone-receptor-positive breast cancer. It works by blocking the production of estrogen in muscle and fat tissue, which is the main source of estrogen in women beyond menopause, after which the ovaries stop making significant levels of estrogen.
  • Prostate cancer is the most common cancer and the second cause of cancer death in men in the United States. About 10% of the initial cases of prostate cancer present with metastatic disease. However, in the rest, metastases will develop despite treatment with surgery, radiation or medical therapy, and those metastases will eventually become refractory to hormonal treatment.
  • the use of chemotherapy in hormone refractory (androgen independent) progressive prostate cancer (HRPC) has been characterized historically by poor efficacy and high toxicity. Newer regimens containing docetaxel have shown a survival benefit over previous palliative regimens. Despite this positive trend, the median survival of HRPC patients treated with docetaxel and prednisone is only 18.9 months; clearly, more effective regimens are required for the treatment of HRPC patients.
  • IGF-1 and IGF-1 R have been produced that block binding of IGF-1 or IGF-2 to IGF-1 R.
  • Such antibodies are described, for example, in International Patent Application No. WO 02/053596, published July 11 , 2002; International Patent Application Nos. WO 05/016967 and WO 05/016970, both published February 24, 2005; International Patent Application No. WO 03/106621 , published December 24, 2003; International Patent Application No. WO 04/083248, published September 30, 2004; International Patent Application No.
  • the present invention is directed to a method for the treatment of an advanced non- hematologic malignancy in a patient in need of such treatment comprising the step of administering to the patient a therapeutically effective amount of an anti-IGF-1 R antibody.
  • the present invention is directed to a method comprising the step of administering to the patient an antibody that specifically binds to IGF-1 R in combination with a therapeutically effective amount of at least one agent selected from the group consisting of an alkylating agent, a folate antagonist, a pyrimidine antagonist, a cytotoxic antibiotic, a platinum compound, a taxane, a vinca alkaloid, a topoisomerase inhibitor, an EGFR inhibitor, and a hormonal therapy agent.
  • the antibody is one that specifically binds to human IGF- 1 R. -A-
  • the anti-lGF-1 R antibody has the following properties: (a) a binding affinity for human IGF-1 R of K d of 8 x 10 "9 or less, and (b) inhibition of binding between human IGF-1 R and IGF-1 with an IC 50 of less than 100 nM.
  • the anti-IGF-1 R antibody comprises (a) a heavy chain comprising the amino acid sequences of CDR-1 , CDR-2, and CDR-3 of an antibody selected from the group consisting of 2.12.1 , 2.13.2, 2.14.3, 4.9.2, 4.17.3, and 6.1.1 , and (b) a light chain comprising the amino acid sequences of CDR-1 , CDR- 2, and CDR-3 of an antibody selected from the group consisting of 2.12.1 , 2.13.2, 2.14.3, 4.9.2, 4.17.3, and 6.1.1 , or (c) sequences having changes from the CDR sequences of an antibody selected from the group consisting of 2.12.1 , 2.13.2, 2.14.3, 4.9.2, 4.17.3, and 6.1.1 , said sequences being selected from the group consisting of conservative changes, wherein the conservative changes are selected from the group consisting of replacement of nonpolar residues by other nonpolar residues, replacement of polar charged residues by other polar uncharged residues, replacement
  • the present invention is also directed to a pharmaceutical composition for the treatment of a non-hematologic malignancy comprising (a) a therapeutically effective amount of an antibody that specifically binds IGF-1 R, (b) a therapeutically effective amount of at least one agent selected from the group consisting of an alkylating agent, a folate antagonist, a pyrimidine antagonist, a cytotoxic antibiotic, a platinum compound, a taxane, a vinca alkaloid, a topoisomerase 1 inhibitor, an EGFR inhibitor, and a hormonal therapy agent; and (c) a pharmaceutically acceptable carrier.
  • Figs. 1A-1C show alignments of the nucleotide sequences of the light chain variable regions from six human anti-IGF-1 R antibodies to each other and to germline sequences.
  • Fig. 1A shows the alignment of the, nucleotide sequences of the variable region of the light chain (VL) of antibodies 2.12.1 (SEQ ID NO: 1 ) 2.13.2 (SEQ ID NO: 5),,2.14.3 (SEQ ID NO: 9) and 4.9.2 (SEQ ID NO: 13) to each other and to the germline V/c A30 sequence (SEQ ID NO: 39).
  • VL variable region of the light chain
  • Fig. 1A shows the alignment of the, nucleotide sequences of the variable region of the light chain (VL) of antibodies 2.12.1 (SEQ ID NO: 1 ) 2.13.2 (SEQ ID NO: 5),,2.14.3 (SEQ ID NO: 9) and 4.9.2 (SEQ ID NO: 13) to each other and to the germline V/c A30 sequence
  • FIG. 1 B shows the alignment of the nucleotide sequence of VL of antibody 4.17.3 (SEQ ID NO: 17) to the germline V/c 012 sequence (SEQ ID NO: 41).
  • Fig. 1C shows the alignment of the nucleotide sequence of VL of antibody 6.1.1 (SEQ ID NO: 21 ) to the germline V/c A27 sequence (SEQ ID NO: 37). The alignments also show the CDR regions of the VL from each antibody.
  • the consensus sequences for Figs. 1A-1C are shown in SEQ ID NOS: 53-55, respectively.
  • Figs. 2A-2D show alignments of the nucleotide sequences of the heavy chain variable regions from six human anti-IGF-1 R antibodies to each other and to germline sequences.
  • Fig. 1 B shows the alignment of the nucleotide sequence of VL of antibody 4.17.3 (SEQ ID NO: 17) to the germline V/c 012 sequence (SEQ ID NO: 41).
  • FIG. 2A shows the alignment of the nucleotide sequence of the VH of antibody 2.12.1 (SEQ ID NO: 3) to the germline VH DP-35 sequence (SEQ ID NO: 29).
  • Fig. 2B shows the alignment of the nucleotide sequence of the VH of antibody 2.14.3 (SEQ ID NO: 11) to the germline VIV- 4/4.35 sequence (SEQ ID NO: 43).
  • Figs. 2C-1 and 2C-2 show the alignments of the nucleotide sequences of the VH of antibodies 2.13.2 (SEQ ID NO: 7), 4.9.2 (SEQ ID NO: 15) and 6.1.1 (SEQ ID NO: 23) to each other and to the germline VH DP-47 sequence (SEQ ID NO: 31).
  • FIG. 2D shows the alignment of the nucleotide sequence of the VH of antibody 4.17.3 (SEQ ID NO: 19) to the germline VH DP-71 sequence (SEQ ID NO: 35). The alignment also shows the CDR regions of the antibodies.
  • the consensus sequences for Figs. 2A-2D are shown in SEQ ID NOS: 56-59, respectively.
  • Fig. 3A shows the number of mutations in different regions of the heavy and light chains of 2.13.2 and 2.12.1 compared to the germline sequences.
  • Figs. 3A-D show alignments of the amino acid sequences from the heavy and light chains of antibodies 2.13.2 and 2.12.1 with the germline sequences from which they are derived.
  • Fig. 3B shows an alignment of the amino acid sequence of the heavy chain of antibody 2.13.2 (SEQ ID NO: 45) with that of germline sequence DP-47(3-23)/D6-19/JH6 (SEQ ID NO: 46).
  • Fig. 3C shows an alignment of the amino acid sequence of the light chain of antibody 2.13.2 (SEQ ID NO: 47) with that of germline sequence A30/Jk2 (SEQ ID NO: 48).
  • Fig. 3D shows an alignment of the amino acid sequence of the heavy chain of antibody 2.12.1 (SEQ ID NO: 49) with that of germline sequence DP-35(3-11 )/D3-3/JH6 (SEQ ID NO: 50).
  • Fig. 3E shows an alignment of the amino acid sequence of the light chain of antibody 2.12.1 (SEQ ID NO: 51 ) with that of germline sequence A30/Jk1 (SEQ ID NO: 52).
  • the signal sequences are in italic, the CDRs are underlined, the constant domains are bold, the framework (FR) mutations are highlighted with a plus sign ("+") above the amino acid residue and CDR mutations are highlighted with an asterisk above the amino acid residue.
  • Figure 4 shows that anti-IGF-1 R antibodies 2.13.2 and 4.9.2 reduce IGF-1 R phosphotyrosine signal in 3T3-IGF-1 R tumors.
  • Figure 5 shows that anti-IGF-1 R antibody 2.13.2 inhibits 3T3-IGF-1 R tumor growth in vivo.
  • the present invention are directed to the treatment of non-hematologic malignancies, including breast, lung, brain, skin, ovarian, prostate, head and neck, colorectal, gastric, bladder, renal, esophageal, and pancreatic cancers, as well as solid tumors of childhood. Treatment of both early stage and advanced (metastatic) cancers are within the scope of the present invention.
  • the method of the present invention is used in the treatment of breast cancer, prostate cancer, and non-small cell lung cancer (NSCLC).
  • NSCLC non-small cell lung cancer
  • alkylating agents are a class of drugs that alkylate DNA, restricting uncoiling and replication of strands.
  • Alkylating agents include cyclophosphamide (CYTOXAN), ifosfamide (IFEX), mechlorethamine hydrochloride (MUSTARGEN), thiotepa (THIOPLEX), streptozotocin (ZANOSAR), carmustine (BICNU, GLIADEL WAFER), lomustine (CEENU), and dacarbazine (DTIC-DOME).
  • a preferred alkylating agent for use in the methods of the present invention is cyclophosphamide.
  • Folate antagonists bind to dihydrofolate reductase (DHFR) and interfere with pyrimidine (thymidine) synthesis.
  • Methotrexate MATREX, FOLEX, TREXALL
  • trimetrexate NEUTREXIN
  • pemetrexed is folate antagonists suitable for use in the methods of the present invention.
  • pemetrexed also inhibits thymidylate synthase and glycinamide ribonucleotide formyl transferase, two other folate-dependent enzymes involved in thymidine synthesis.
  • Pyrimidine antagonists inhibit enzymes involved in pyrimidine synthesis. As pyrimidine analogs, they also interfere with DNA production by competing with normal nucleotides for incorporation into the DNA molecule.
  • Pyrimidine antagonists suitable for use in the methods of the present invention include 5-fluorouracil (5-FU); capecitabine (XELODA), a prodrug of 5'-deoxy-5-fluorouridine (5'-FDUR), which is enzymatically converted to 5-FU in vivo; raltitrexed (TOMUDEX); tegafur-uracil (UFTORAL); and gemcitabine (GEMZAR).
  • Anthracycline antibiotics exert a cytotoxic effect by inhibiting the uncoiling of DNA by intercalation between DNA strands.
  • Anthracyclines and anthracyclines derivatives include doxorubicin hydrochloride (ADRIAMYCIN, RUBEX, DOXIL), epirubicin hydrochloride (ELLENCE, PHARMORUBICIN), daunorubicin (CERUBIDINE, DAUNOXOME), nemorubicin, idarubicin hydrochloride (IDAMYCIN PFS, ZAVEDOS) and mitoxantrone (DHAD, NOVANTRONE).
  • Preferred anthracyclines for use with the present invention include doxorubicin and epirubicin.
  • Other cytotoxic antibiotics are useful as cancer chemotherapeutic agents and suitable for use in the present invention. These include dactinomycin (actinomycin D, COSMEGEN), plicamycin (MITHRACIN), mitomycin (MUTAMYCIN), and bleomycin (BLENOXANE). Dactinomycin is particularly preferred.
  • Platinum compounds exert their anti-neoplastic effect by intercalation and intracalation between DNA strands, which inhibits uncoiling of the DNA.
  • Platinum compounds useful in the methods of the present invention include cisplatin (PLATINOL) and carboplatin (PARAPLATIN). Taxanes promote assembly of microtubules while inhibiting their disassembly into tubulin, thereby blocking a cell's ability to break down the mitotic spindle during mitosis. They have demonstrated significant activity against many solid tumors as single agent therapy and in combination with other chemotherapy agents.
  • One embodiment of the combination therapy of the present invention includes the use of one or more taxanes in combination with the IGF- 1 R antibody. Suitable taxanes for use in combination with the IGF-1 R antibody include docetaxel (TAXOTERE) and paciitaxel (TAXOL).
  • Vinca alkaloids like taxanes, are "spindle poisons," acting on the microtubules that form the mitotic spindle. They inhibit mitosis by interfering with microtubule assembly, keeping the spindle from being formed.
  • Vinca alkaloids include vindesine (ELDISINE), vinblastine sulfate (VELBAN), vincristine sulfate (ONCOVIN) and vinorelbine tartrate (NAVELBINE).
  • a preferred vinca alkaloid for use in the methods of the present invention is vinorelbine.
  • camptothecin analogs act through inhibition of topoisomerase I, an enzyme critical for DNA replication and packaging. Levels of topoisomerase I are higher in tumor cells than in normal tissue. Camptothecin analogs useful in the methods of the present invention. include irinotecan (CAMPTOSAR) and topotecan (HYCAMTIN). lrinotecan is particularly preferred.
  • Inhibitors of topoisomerase Il interfere with the normal DNA breakage resealing process (as do inhibitors of topoisomerase I), and they also interfere with the separation of newly replicated chromosomes, resulting in clastogenic mutation and potential cell death.
  • the anthracyline antibiotics discussed above exhibit topoisomerase Il inhibitory activity.
  • podophyllotoxin derivatives suitable for use in the present invention include etoposide (VEPESID), etoposide phosphate (ETOPOPHOS), and teniposide
  • Etoposide is particularly preferred.
  • EGFR epidermal growth factor receptor
  • TK tyrosine kinase
  • EGFR- TK inhibitors may selectively target one of the members of the EGFR family (EGFR (also known as HER1 or ErbB-1), HER2/neu (also known as ErbB-2), HER3 (also known as ErbB- 3), or HER4 (also known as ErbB-4)), or may target two or more of them.
  • EGFR also known as HER1 or ErbB-1
  • HER2/neu also known as ErbB-2
  • HER3 also known as ErbB- 3
  • HER4 also known as ErbB-4
  • EGFR-TK inhibitors suitable for use in the present invention include gefitinib (IRESSA), erlotinib (TARCEVA), trastuzumab (HERCEPTIN), panitumumab (ABX-EGF; Abgenix/Amgen), lapatinib (GlaxoSmithKline), CI-1033 (Pfizer), GW2016 (GlaxoSmithKline), EKB-569 (Wyeth), PKI-166 (Novartis), CP-724,714 (Pfizer), and BIBX-1382 (Boeringer-lngelheim). Additional EGFR-TK inhibitors are described in United States Patent Publication No. US 2002-0169165A1 , published November 14, 2002.
  • Another embodiment of the combination therapy of the present invention includes the use of hormonal therapy in combination with the IGF-1 R antibody, particularly anti-estrogens in the treatment of breast cancer.
  • hormonal treatments compete with estrogen for binding sites in breast tissue. These include tamoxifen citrate (NOLVADEX) and fulvestrant (FASLODEX).
  • anti-androgens block testosterone receptors and therefore are useful in the treatment of androgen-dependent prostate cancer.
  • aromatase inhibitors This class of hormonal agents inactivate aromatase, the enzyme which converts androgens to estrogens.
  • aromatase inhibitors suitable for use in combination with the IGF-1 R antibody include anastrozole (ARIMIDEX), letrozole (FEMARA), exemestane (AROMASIN), and fadrozole hydrochloride.
  • Exemestane is a particularly preferred aromatase inhibitor for use in the methods of the present invention.
  • Co-administration of the antibody with an additional therapeutic agent encompasses administering a pharmaceutical composition comprising both the anti- IGF-1 R antibody and one or more additional therapeutic agents, and administering two or more separate pharmaceutical compositions, one comprising the anti-IGF-1 R antibody and the other(s) comprising the additional therapeutic agent(s).
  • co ⁇ administration or combination (conjoint) therapy generally mean that the antibody and additional therapeutic agents are administered at the same time as one another, it also encompasses simultaneous, sequential or separate dosing of the individual components of the treatment.
  • the present invention also encompasses the administration of other therapeutic agents in addition to the first and second components, either concurrently with one or more of those components, or sequentially.
  • therapeutic agents include analgesics, cancer vaccines, anti-vascular agents, anti-proliferative agents, and anti-emetic agents.
  • Preferred anti-emetic agents include aprepitant, ondansetron hydrochloride, granisetron hydrochloride, and metoclopramide.
  • compositions according to the invention are preferably compositions which can be administered parentally. However, these compositions may be administered orally or intraperitoneal ⁇ in the case of localized regional therapies.
  • the choice of therapeutic agents to be used in combination with IGF-1 R antibodies, and the timing of their use, will be determined in part by the type and stage of the cancer that is being treated. For example, in early breast cancer (where the cancer has not spread outside the breast), surgery and radiation are generally followed by adjuvant chemotherapy or adjuvant hormonal therapy, either of which may be combined with IGF-1R antibodies in the methods of the present invention.
  • Typical adjuvant chemotherapy for early breast cancer includes cyclophosphamide, methotrexate and 5-FU (“CMF”); 5-FU, doxorubicin, and cyclophosphamide (“FAC”); docetaxel, doxorubicin, and cyclophosphamide (“TAG”); doxorubicin and cyclophosphamide (“AC”); doxorubicin and cyclophosphamide followed by paclitaxel (“AC and T”); and 5-FU, epirubicin, and cyclophosphamide (“FEC”). Tamoxifen is a preferred hormonal treatment at this stage.
  • IGF-1R antibodies may be administered in conjunction with the chemotherapeutic or hormonal therapy agents whether they are used either before or after surgery/radiation.
  • Typical chemotherapy regimes for locally advanced breast cancer include FAC, AC, FEC, and doxorubicin plus docetaxel ("AT").
  • Metastatic breast cancer has spread to other parts of the body from the breast in which it started.
  • Chemotherapy optionally may be preceded by hormonal therapy.
  • First line hormonal therapy currently includes tamoxifen and anastrozole.
  • First line chemotherapy regimens currently include FAC, TAC, docetaxel plus epirubicin, docetaxel, paclitaxel, capecitabine, vinorelbine, and trastuzumab.
  • Second line chemotherapy treatments include docetaxel, alone or in combination with capecitabine. The methods of the present invention are suitable for use both as first line therapy and second line therapy.
  • first line treatment of inoperable Stage IHB i.e. cancer has spread to structures near the lung, to lymph nodes in the mediastinum, or to lymph nodes on the other side of the chest or in the lower neck
  • Stage IV i.e. cancer has spread to other parts of the body or to another lobe of the lungs
  • NSCLC non-small cell lung cancer
  • NSCLC neurodegenerative medicine
  • Other treatment regimens for NSCLC include paclitaxel alone or with cisplatin or gemcitabine; docetaxel alone or with cisplatin or gemcitabine; vinorelbine alone or with gemcitabine; irinotecan alone or with gemcitabine; pemetrexed; and gefitinib.
  • IGF-1 R signaling through IGF-1 R is required for the tumorgenicity of cell lines and has been shown to decrease the cytotoxicity of chemotherapy, and that blocking IGF-1 R activity enhances the effectiveness of current therapies and prevents tumor progression in animal models. It was therefore expected that an inhibitor of IGF-1 R such as the antibodies of the present invention would reduce tumor cell survival and enhance the efficacy of chemotherapy when given in combination.
  • the serum concentration of anti- IGF-1 R antibodies that led to 50% growth inhibition was 20 ⁇ g/ml at Day 1 , and 13 ⁇ g/ml at Day 9. Similar anti-tumor studies were extended to human tumor xenograft models. As a single agent, anti-IGF-1 R antibodies inhibited the growth of several xenograft models including breast, lung and colorectal carcinomas. The combination of anti-IGF-1 R antibodies with paclitaxel or carboplatin was tested in the H460 and EBC-1 human NSCLC tumor xenograft models. Combination of anti-IGF-1 R antibodies with those agents increased their tumor growth inhibition compared to each agent alone.
  • an “antibody” refers to an intact immunoglobulin or to an antigen-binding portion thereof that competes with the intact antibody for specific binding.
  • Antigen-binding portions may be produced by recombinant DNA techniques or by enzymatic or chemical cleavage of intact antibodies.
  • Antigen-binding portions include, inter alia, Fab, Fab', F(ab') 2 , Fv, dAb, and complementarity determining region (CDR) fragments, single-chain antibodies (scFv), chimeric antibodies, diabodies and polypeptides that contain at least a portion of an immunoglobulin that is sufficient to confer specific antigen binding to the polypeptide.
  • Immunoglobulin chains exhibit the same general structure of relatively conserved framework regions (FR) joined by three hypervariable regions, also called complementarity determining regions or CDRs.
  • the CDRs from the two chains of each pair are aligned by the framework regions, enabling binding to a specific epitope.
  • both light and heavy chains comprise the domains FR1 , CDR1 , FR2, CDR2, FR3, CDR3 and FR4.
  • the assignment of amino acids to each domain is in accordance with the definitions of Kabat, Sequences of Proteins of Immunological Interest (National Institutes of Health, Bethesda, Md. (1987 and 1991)), or Chothia & Lesk, J. MoI. Biol. 196:901-917 (1987); Chothia et al., Nature 342:878-883 (1989).
  • isolated antibody is an antibody that (1) is not associated with naturally- associated components, including other naturally-associated antibodies, that accompany it in its native state, (2) is free of other proteins from the same species, (3) is expressed by a cell from a different species, or (4) does not occur in nature.
  • isolated antibodies include an anti-IGF-1R antibody that has been affinity purified using IGF-1 R is an isolated antibody, an anti-IGF-1 R antibody that has been synthesized by a hybridoma or other cell line in vitro, and a human anti-IGF-1 R antibody derived from a transgenic mouse.
  • chimeric antibody refers to an antibody that contains one or more regions from one antibody and one or more regions from one or more other antibodjes.
  • one or more of the CDRs are derived from a human anti-IGF-1 R antibody.
  • all of the CDRs are derived from a human anti-IGF-1 R antibody.
  • the CDRs from more than one human anti-IGF-1 R antibodies are mixed and matched in a chimeric antibody.
  • the framework regions may be derived from one of the same anti-IGF-1 R antibodies, from one or more different antibodies, such as a human antibody, or from a humanized antibody.
  • epitopic determinants includes any protein determinant capable of specific binding to an immunoglobulin or T-cell receptor.
  • Epitopic determinants usually consist of chemically active surface groupings of molecules such as amino acids or sugar sides chains and usually have specific three dimensional structural characteristics, as well as specific charge characteristics.
  • An antibody is said to specifically bind an antigen when the dissociation constant is ⁇ 1 ⁇ M, preferably ⁇ 100 nM and most preferably ⁇ 10 nM.
  • the term "substantial identity” means that two peptide sequences, when optimally aligned, such as by the programs GAP or BESTFIT using default gap weights, share at least 75% or 80% sequence identity, preferably at least 90% or 95% sequence identity, even more preferably at least 98% or 99% sequence identity.
  • residue positions that are not identical differ by conservative amino acid substitutions.
  • a “conservative amino acid substitution” is one in which an amino acid residue is substituted by another amino acid residue having a side chain (R group) with similar chemical properties (e.g., charge or hydrophobicity). In general, a conservative amino acid substitution will not substantially change the functional properties of a protein.
  • the percent sequence identity or degree of similarity may be adjusted upwards to correct for the conservative nature of the substitution. Means for making this adjustment are well-known to those of skill in the art. See, e.g., Pearson, Methods MoI. Biol. 24: 307-31 (1994).
  • Examples of groups of amino acids that have side chains with similar chemical properties include 1 ) aliphatic side chains: glycine, alanine, valine, leucine and isoleucine; 2) aliphatic-hydroxyl side chains: serine and threonine; 3) amide-containing side chains: asparagine and glutamine; 4) aromatic side chains: phenylalanine, tyrosine, and tryptophan; 5) basic side chains: lysine, arginine, and histidine; and 6) sulfur-containing side chains are cysteine and methionine.
  • Conservative amino acids substitution groups include: valine-leucine-isoleucine, phenylalanine-tyrosine, lysine-arginine, alanine-valine, glutamate-aspartate, and asparagine-glutamine.
  • Preferred amino acid substitutions are those which: (1 ) reduce susceptibility to proteolysis, (2) reduce susceptibility to oxidation, (3) alter binding affinity for forming protein complexes, (4) alter binding affinities, and (4) confer or modify other physicochemical or functional properties of such analogs.
  • Analogs can include various mutations of a sequence other than the naturally-occurring peptide sequence.
  • single or multiple amino acid substitutions may be made in the naturally-occurring sequence (preferably in the portion of the polypeptide outside the domain(s) forming intermolecular contacts.
  • a conservative amino acid substitution should not substantially change the structural characteristics of the parent sequence (e.g., a replacement amino acid should not tend to break a helix that occurs in the parent sequence, or disrupt other types of secondary structure that characterizes the parent sequence).
  • the phrase "in combination with” encompasses simultaneous, sequential or separate dosing of the individual components of the treatment.
  • the antibody may be administered once every three days, while the additional therapeutic agent is administered once daily.
  • the antibody may be administered prior to or subsequent to treatment of the disorder with the additional therapeutic agent.
  • the anti-IGF-1R antibody may be administered prior to or subsequent to other therapy, such as radiotherapy, chemotherapy, photodynamic therapy, surgery or other immunotherapy.
  • the terms “concurrently” and “simultaneously” are used interchangeably and mean the compounds of the combination therapy of the present invention are administered (1 ) simultaneously in time, or (2) at different times during the course of a common treatment schedule.
  • the term “sequentially” as used herein means administration of the a first component, followed by administration of a second component.
  • Anti-IGF-1 R antibodies may be the first component or the second component.
  • the second component can be administered substantially immediately after the first component, or the second component can be administered an effective time period after the first component; the effective time period is the amount of time given for realization of maximum benefit from the administration of the first component.
  • the term "patient” includes mammals.
  • the mammal is a human.
  • treating means reversing, alleviating, inhibiting the progress of, or preventing the disorder or condition to which such term applies, or one or more symptoms of such disorder or condition.
  • treatment refers to the act of treating as “treating” is defined immediately above.
  • Human antibodies avoid certain of the problems associated with antibodies that possess mouse or rat variable and/or constant regions. More preferred are fully human anti- human IGF-1 R antibodies. Fully human anti-IGF-1R antibodies are expected to minimize the immunogenic and allergic responses intrinsic to mouse or mouse-derivatized monoclonal antibodies (Mabs) and thus to increase the efficacy and safety of the administered antibodies. The use of fully human antibodies can be expected to provide a substantial advantage in the treatment of chronic and recurring human diseases, such as inflammation and cancer, which may require repeated antibody administrations. In another embodiment, the invention provides an anti-IGF-1 R antibody that does not bind complement.
  • the anti-IGF-1 R antibodies bind to IGF-1 R with high affinity.
  • the anti-IGF-1 R antibody binds to IGF-1 R with a K d of 1 x 10 '8 M or less.
  • the antibody binds to IGF-1 R with a K d or 1 x 10 "9 M or less.
  • the antibody binds to IGF-1 R with a K d or 5 x 10 '10 M or less.
  • the antibody binds to IGF-1 R with a K d or 1 x 10 '10 M or less.
  • the antibody binds to IGF-1 R with substantially the same K d as an antibody selected from 2.12.1 , 2.13.2, 2.14.3, 3.1.1 , 4.9.2, 4.17.3 or 6.1.1. In another preferred embodiment, the antibody binds to IGF-1 R with substantially the same K d as an antibody that comprises one or more CDRs from an antibody selected from 2.12.1 , 2.13.2, 2.14.3, 3.1.1 , 4.9.2, 4.17.3 or 6.1.1.
  • the invention also employs an anti-IGF-1 R antibody that binds the same antigen or epitope as a human anti-IGF-1 R antibody.
  • the invention may also employ an anti-IGF-1 R antibody that cross-competes with a human anti-IGF-1 R antibody.
  • the human anti-IGF-1 R antibody is 2.12.1 , 2.13.2, 2.14.3, 3.1.1 , 4.9.2, 4.17.3 or 6.1.1.
  • the human anti-IGF-1 R comprises one or more CDRs from an antibody selected from 2.12.1 , 2.13.2, 2.14.3, 3.1.1 , 4.9.2, 4.17.3 or 6.1.1
  • variable sequences encoded by a human K gene.
  • the variable sequences are encoded by either the V/c A27, A30 or 012 gene family.
  • the variable sequences are encoded by a human V/c A30 gene family.
  • the light chain comprises no more than ten amino acid substitutions from the germline V/c A27, A30 or 012, preferably no more than six amino acid substitutions, and more preferably no more than three amino acid substitutions.
  • amino acid substitutions are conservative substitutions.
  • the VL of the anti-IGF-1 R antibody contains the same amino acid substitutions, relative to the germline amino acid sequence, as any one or more of the VL of antibodies 2.12.1 , 2.13.2, 2.14.3, 3.1.1 , 4.9.2, 4.17.3 or 6.1.1.
  • the light chain comprises an amino acid sequence that is the same as the amino acid sequence of the VL of 2.12.1 , 2.13.2, 2.14.3, 3.1.1 , 4.9.2, 4.17.3 or 6.1.1.
  • the light chain comprises amino acid sequences that are the same as the CDR regions of the light chain of 2.12.1, 2.13.2, 2.14.3, 3.1.1 , 4.9.2, 4.17.3 or 6.1.1.
  • the light chain comprises an amino acid sequence from at least one CDR region of the light chain of 2.12.1 , 2.13.2, 2.14.3, 3.1.1 , 4.9.2, 4.17.3 or 6.1.1.
  • the present invention can also be carried out using an anti-IGF-1 R antibody or portion thereof comprising a human heavy chain or a sequence derived from a human heavy chain.
  • the heavy chain amino acid sequence is derived from a human V H DP-35, DP-47, DP-70, DP-71 or VIV-4/4.35 gene family.
  • the heavy chain amino acid sequence is derived from a human VH DP-47 gene family.
  • the heavy chain comprises no more than eight amino acid changes from germline V H DP-35, DP-47, DP-70, DP-71 or VIV-4/4.35, more preferably no more than six amino acid changes, and even more preferably no more than three amino acid changes.
  • the VH of the anti-IGF-1 R antibody contains the same amino acid substitutions, relative to the germline amino acid sequence, as any one or more of the VH of antibodies 2.12.1 , 2.13.2, 2.14.3, 3.1.1 , 4.9.2, 4.17.3 or 6.1.1.
  • the amino acid substitutions are made in the same position as those found in any one or more of the VH of antibodies 2.12.1 , 2.13.2, 2.14.3, 3.1.1 , 4.17.3., 4.9.2 or 6.1.1 , but conservative amino acid substitutions are made rather than using the same amino acid.
  • the heavy chain comprises an amino acid sequence that is the same as the amino acid sequence of the VH of 2.12.1 , 2.13.2, 2.14.3, 3.1.1 , 4.9.2, 4.17.3 or 6.1.1.
  • the heavy chain comprises amino acid sequences that are the same as the CDR regions of the heavy chain of 2.12.1 , 2.13.2, 2.14.3, 3.1.1, 4.9.2, 4.17.3 or 6.1.1.
  • the heavy chain comprises an amino acid sequence from at least one CDR region of the heavy chain of 2.12.1 , 2.13.2, 2.14.3, 3.1.1 , 4.9.2, 4.17.3 or 6.1.1.
  • the heavy chain comprises amino acid sequences from CDRs from different heavy chains.
  • the CDRs from different heavy chains are obtained from 2.12.1 , 2.13.2, 2.14.3, 3.1.1 , 4.9.2, 4.17.3 or 6.1.1.
  • the invention employs an anti-IGF-1 R antibody that inhibits the binding of IGF-1 to IGF-1 R or the binding of IGF-2 to IGF-1 R.
  • the IGF-1 R is human.
  • the anti-IGF-1 R antibody is a human antibody.
  • the antibody or portion thereof inhibits binding between IGF-1 R and IGF-1 with an IC 50 of no more than 100 nM.
  • the IC 50 is no more than 10 nM.
  • the IC 50 is no more than 5 nM.
  • the IC 50 can be measured by any method known in the art. Typically, an IC 50 can be measured by ELISA or RIA. In a preferred embodiment, the IC 50 is measured by RIA.
  • the invention employs an anti-IGF-1 R antibody that prevents activation of the IGF-1 R in the presence of IGF-i.
  • the antibody causes the downregulation of IGF-1 R from a cell treated with the antibody.
  • the antibody is selected 2.12.1 , 2.13.2, 2.14.3, 3.1.1 , 4.9.2, or 6.1.1 , or comprises a heavy chain, light chain or antigen-binding region thereof.
  • Human antibodies can be produced by immunizing a non-human animal comprising of some or all of the human immunoglobulin locus with an IGF-1 R antigen.
  • the non-human animal is a XENOMOUSETM, which is an engineered mouse strain that comprises large fragments of the human immunoglobulin loci and is deficient in mouse antibody production. See, e.g., Green et al. Nature Genetics 7:13-21 (1994) and United States Patent Nos. 5,916,771, 5,939,598, 5,985,615, 5,998,209, 6,075,181 , 6,091 ,001 , 6,114,598, and 6,130,364. See also International Patent Application Nos.
  • WO 91/10741 published July 25, 1991 ; WO 94/02602, published February 3, 1994; WO 96/34096 and WO 96/33735, both published October 31 , 1996; WO 98/16654, published April 23, 1998; WO 98/24893, published June 11, 1998; WO 98/50433, published November 12, 1998; WO 99/45031 , published September 10, 1999; WO 99/53049, published October 21 , 1999; WO 00/09560, published February 24, 2000; and WO 00/037504, published June 29, 2000.
  • the XENOMOUSE TM produces an adult-like human repertoire of fully human antibodies, and generates antigen-specific human monoclonal antibodies.
  • a second generation XENOMOUSETM contains approximately 80% of the human antibody repertoire through introduction of megabase sized, germline configuration YAC fragments of the human heavy chain loci and K light chain loci. See Mendez et al. Nature Genetics 15:146-156 (1997), Green and Jakobovits J. Exp. Med. 188:483-495 (1998).
  • the IGF-1 R antigen can be administered with an adjuvant to stimulate the immune response.
  • adjuvants include complete or incomplete Freund's adjuvant, RIBI (muramyl dipeptides) or ISCOM (immunostimulating complexes).
  • RIBI muramyl dipeptides
  • ISCOM immunological complexes
  • Such adjuvants may protect the polypeptide from rapid dispersal by sequestering it in a local deposit, or they may contain substances that stimulate the host to secrete factors that are chemotactic for macrophages and other components of the immune system.
  • the nucleic acid molecule encoding the variable region of the light chain may be derived from the A30, A27 or 012 VK gene.
  • the light chain is derived from the A30 VK gene.
  • the nucleic acid molecule encoding the light chain contains no more than ten amino acid changes from the germline A30 VK gene, preferably no more than six amino acid changes, and even more preferably no more than three amino acid changes.
  • the antibody contains no greater than ten amino acid changes in either the VH or VL regions of the mutated anti-IGF-1 R antibody compared to the anti-IGF-1 R antibody prior to mutation.
  • SEQ ID NOS: 2, 6, 10, 14, 18 and 22 provide the amino acid sequences of the variable regions of six anti-IGF-1 R K light chains.
  • SEQ ID NOS: 4, 8, 12, 16, 20 and 24 provide the amino acid sequences of the variable regions of six anti-IGF-1 R heavy chains.
  • SEQ ID NO: 26 depicts the amino acid sequence and
  • SEQ ID NO: 25 depicts the nucleic acid sequence encoding the constant region of the light chain of the anti-IGF-1 R antibodies 2.12.1 , 2.13.2, 2.14.3, 3.1.1 , 4.9.2, 4.17.3 and 6.1.1.
  • SEQ ID NO: 28 depicts the amino acid sequence and SEQ ID NO: 27 depicts the nucleic acid sequence encoding the constant region of the heavy chain of the anti-IGF-1 R antibodies 2.12.1 , 2.13.2, 2.14.3, 3.1.1 , 4.9.2, 4.17.3 and 6.1.1.
  • SEQ ID NOS: 30, 32, 34, 36 and 44 provide the amino acid sequences of the germline heavy chains DP-35, DP-47, DP-70, DP-71 and VIV-4, respectively.
  • SEQ ID NO: 33 provides the nucleotide sequence of the germline heavy chain DP-70.
  • SEQ ID NOS: 38, 40 and 42 provide the amino acid sequences of the three germline K light chains from which the six anti-IGF-1 R K light chains are derived.
  • the anti-IGF-1 R antibodies can be incorporated into pharmaceutical compositions suitable for administration to a subject.
  • the pharmaceutical composition comprises an antibody and a pharmaceutically acceptable carrier.
  • pharmaceutically acceptable carrier includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like that are physiologically compatible.
  • pharmaceutically acceptable carriers include water, saline, phosphate buffered saline, dextrose, glycerol, ethanol and the like, as well as combinations thereof.
  • isotonic agents for example, sugars, polyalcohols such as mannitol, sorbitol, or sodium chloride in the
  • compositions may be in a variety of forms. These include, for example, liquid, semi-solid and solid dosage forms, such as liquid solutions (e.g., injectable and infusible solutions), dispersions or suspensions, tablets, pills, powders, liposomes and suppositories. The preferred form depends on the intended mode of administration and therapeutic application. Typical preferred compositions are in the form of injectable or infusible solutions, such as compositions similar to those used for passive immunization of humans with other antibodies.
  • liquid solutions e.g., injectable and infusible solutions
  • dispersions or suspensions e.g., tablets, pills, powders, liposomes and suppositories.
  • the preferred form depends on the intended mode of administration and therapeutic application.
  • Typical preferred compositions are in the form of injectable or infusible solutions, such as compositions similar to those used for passive immunization of humans with other antibodies.
  • a preferred mode of administration is parenteral (e.g., intravenous, subcutaneous, intraperitoneal, intramuscular, or infusion).
  • the antibody is administered by intravenous infusion or injection.
  • the antibody is administered by intramuscular or subcutaneous injection.
  • the route and/or mode of administration will vary depending upon the desired results.
  • compositions typically must be sterile and stable under the conditions of manufacture and storage.
  • the composition can be formulated as a solution, microemulsion, dispersion, liposome, or other ordered structure suitable to high drug concentration.
  • Sterile injectable solutions can be prepared by incorporating the anti-IGF-1 R antibody in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization.
  • dispersions are prepared by incorporating the active compound into a sterile vehicle that contains a basic dispersion medium and the required other ingredients from those enumerated above.
  • the preferred methods of preparation are vacuum drying and freeze-drying that yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.
  • the proper fluidity of a solution can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants.
  • Prolonged absorption of injectable compositions can be brought about by including in the composition an agent that delays absorption, for example, monostearate salts and gelatin.
  • the active compound may be prepared with a carrier that will protect the compound against rapid release, such as a controlled release formulation, including implants, transdermal patches, and microencapsulated delivery systems.
  • a controlled release formulation including implants, transdermal patches, and microencapsulated delivery systems.
  • Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Many methods for the preparation of such formulations are patented or generally known to those skilled in the art. See, e.g., Sustained and Controlled Release Drug Delivery Systems, J. R. Robinson, ed., Marcel Dekker, Inc., New York, 1978.
  • the pharmaceutical composition may include a "therapeutically effective amount” or a “prophylactically effective amount” of an antibody or antibody portion of the invention.
  • a “therapeutically effective amount” refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired therapeutic result.
  • a therapeutically effective amount of the antibody or antibody portion may vary according to factors such as the disease state, age, sex, and weight of the individual, and the ability of the antibody or antibody portion to elicit a desired response in the individual.
  • a therapeutically effective amount is also one in which any toxic or detrimental effects of the antibody or antibody portion are outweighed by the therapeutically beneficial effects.
  • a “prophylactically effective amount” refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired prophylactic result. Typically, since a prophylactic dose is used in subjects prior to or at an earlier stage of disease, the prophylactically effective amount will be less than the therapeutically effective amount.
  • Dosage regimens may be adjusted to provide the optimum desired response. For example, a single bolus may be administered, several divided doses may be administered over time or the dose may be proportionally reduced or increased as indicated by the exigencies of the therapeutic situation.
  • Pharmaceutical composition comprising the antibody or comprising a combination therapy comprising the antibody and one or more additional therapeutic agents may be formulated for single or multiple doses. It is especially advantageous to formulate parenteral compositions in dosage unit form for ease of administration and uniformity of dosage.
  • Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the mammalian subjects to be treated; each unit containing a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier.
  • a particularly useful formulation is 5 mg/ml anti-IGF-1 R antibody in a buffer of 2OmM sodium citrate, pH 5.5, 14OmM NaCI, and 0.2mg/ml polysorbate 80.
  • the antibody may be administered once, or more than once for at least the period of time until the condition is treated, palliated or cured.
  • the antibody generally will be administered for as long as the tumor is present provided that the antibody causes the tumor or cancer to stop growing or to decrease in weight or volume.
  • the antibody will generally be administered as part of a pharmaceutical composition as described supra.
  • the dosage of antibody will generally be in the range of 0.025-100 mg/kg, more preferably 0.05-50 mg/kg, more preferably 0.05-20 mg/kg, and even more preferably 0.1-10 mg/kg. It is to be noted that dosage values may vary with the type and severity of the condition to be alleviated.
  • the antibody may be administered from three times daily to once every six months.
  • the administration may be on a schedule such as three times daily, twice daily, once daily, once every two days, once every three days, once weekly, once every two weeks, once every month, once every two months, once every three months and once every six months.
  • the antibody may be administered via an oral, mucosal, buccal, intranasal, inhalable, intravenous, subcutaneous, intramuscular, parenteral, intratumor or topical route.
  • the antibody may be administered at a site distant from the site of the tumor.
  • the antibody may also be administered continuously via a minipump.
  • the antibody may be administered in an aerosol or inhalable form. Dry aerosol in the form of finely divided solid particles that are not dissolved or suspended in a liquid are also useful in the practice of the present invention.
  • the pharmaceutical formulations of the present invention may be administered in the form of an aerosol spray using for example, a nebulizer such as those described in U.S. Patent Nos. 4,624,251 ; 3,703,173; 3,561 ,444; and 4,635,627.
  • the serum concentration of the antibody may be measured by any method known in the art.
  • the antibody may also be administered prophylactically in order to prevent a cancer or tumor from occurring.
  • the antibody employed in the method of the invention can be labeled. This can be done by incorporation of a detectable marker, e.g., incorporation of a radiolabeled amino acid or attachment to a polypeptide of biotinyl moieties that can be detected by marked avidin (e.g., streptavidin containing a fluorescent marker or enzymatic activity that can be detected by optical or colorimetric methods). In certain situations, the label or marker can also be therapeutic. Various methods of labeling polypeptides and glycoproteins are known in the art and may be used.
  • labels for polypeptides include, but are not limited to, the following: radioisotopes or radionuclides (e.g., 3 H, 14 C, 15 N, 35 S, 90 Y, 99 Tc, 111 In, 125 I, 131 I), fluorescent labels (e.g., FITC, rhodamine, lanthanide phosphors), enzymatic labels (e.g., horseradish peroxidase, ⁇ -galactosidase, luciferase, alkaline phosphatase), chemiluminescent, biotinyl groups, predetermined polypeptide epitopes recognized by a secondary reporter (e.g., leucine zipper pair sequences, binding sites for secondary antibodies, metal binding domains, epitope tags).
  • labels are attached by spacer arms of various lengths to reduce potential steric hindrance.
  • the antibodies employed in the present invention are preferably derived from cells that express human immunoglobulin genes.
  • Use of transgenic mice is known in the art to produce such "human” antibodies.
  • One such method is described in U.S. Patent Application Serial No. 08/759,620, filed December 3, 1996. See also Mendez et al. Nature Genetics 15:146-156 (1997); Green and Jakobovits J. Exp. Med. 188:483-495 (1998); European Patent No. EP 0 463 151 (grant published June 12, 1996); and International Patent Application Nos. WO 94/02602, published February 3, 1994; WO 96/34096, published October 31 , 1996; and WO 98/24893, published June 11 , 1998.
  • Antibody fragments such as Fv, F(ab') 2 and Fab may be prepared by cleavage of the intact protein, e.g. by protease or chemical cleavage.
  • a truncated gene is designed.
  • a chimeric gene encoding a portion of the F(ab') 2 fragment would include DNA sequences encoding the CH1 domain and hinge region of the H chain, followed by a translational stop codon to yield the truncated molecule.
  • consensus sequences encoding the heavy and light chain J regions may be used to design oligonucleotides for use as primers to introduce useful restriction sites into the J region for subsequent linkage of V region segments to human C region segments.
  • C region cDNA can be modified by site directed mutagenesis to place a restriction site at the analogous position in the human sequence.
  • Expression vectors for use in obtaining the antibodies employed in the invention include plasmids, retroviruses, cosmids, YACs, EBV derived episomes, and the like.
  • a convenient vector is normally one that encodes a functionally complete human CH or CL immunoglobulin sequence, with appropriate restriction sites engineered so that any VH or VL sequence can be easily inserted and expressed.
  • splicing usually occurs between the splice donor site in the inserted J region and the splice acceptor site preceding the human C region, and also at the splice regions that occur within the human CH exons. Polyadenylation and transcription termination occur at native chromosomal sites downstream of the coding regions.
  • the resulting chimeric antibody may be joined to any strong promoter, including retroviral LTRs, e.g. SV-40 early promoter (Okayama et al. MoI. Cell. Bio. 3:280 (1983)), Rous sarcoma virus LTR (Gorman et al. Proc. Natl. Acad. Sci. 79:6777 (1982)), and moloney murine leukemia virus LTR (Grosschedl et al. Cell 41 :885 (1985)); native Ig promoters, etc.
  • retroviral LTRs e.g. SV-40 early promoter (Okayama et al. MoI. Cell. Bio. 3:280 (1983)
  • Rous sarcoma virus LTR Rous sarcoma virus LTR
  • moloney murine leukemia virus LTR Grosschedl et al. Cell 41 :885 (1985)
  • native Ig promoters etc.
  • Antibodies that are generated for use in the invention need not initially possess a particular desired isotype. Rather, the antibody as generated can possess any isotype and can be isotype switched thereafter using conventional techniques. These include direct recombinant techniques (see e.g., U.S. Patent No. 4,816,397), and cell-cell fusion techniques (see e.g., U.S. Patent No. 5,916,771 ).
  • the effector function of the antibodies of the invention may be changed by isotype switching to an IgGI , lgG2, lgG3, lgG4, IgD, IgA, IgE, or IgM for various therapeutic uses.
  • dependence on complement for cell killing can be avoided through the use of bispecifics, immunotoxins, or radiolabels, for example.
  • Bispecific antibodies can be generated that comprise (i) two antibodies: one with a specificity for IGF-1 R and the other for a second molecule (ii) a single antibody that has one chain specific for IGF-1 R and a second chain specific for a second molecule, or (iii) a single chain antibody that has specificity for IGF-1 R and the other molecule.
  • Such bispecific antibodies can be generated using well known techniques, e.g., Fanger et al. Immunol. Methods 4:72-81 (1994); Wright and Harris, supra; and Traunecker et al. Int. J. Cancer (Suppl.) 7:51-52 (1992).
  • Antibodies for use in the invention also include “kappabodies” (III et al. Protein Eng. 10:949-57 (1997)), “minibodies” (Martin et al. EMBO J. 13:5303-9 (1994)), “diabodies” (Holliger et al. Proc. Natl. Acad. Sci. (USA) 90:6444-6448 (1993)), and “janusins” (Traunecker et al. EMSO J. 10:3655-3659 (1991) and Traunecker et al. Int. J. Cancer Suppl. 7:51-52 (1992)) may also be prepared.
  • the antibodies employed can be modified to act as immunotoxins by conventional techniques. See e.g., Vitetta Immunol. Today 14:252 (1993). See also U.S. Patent No. 5,194,594. Radiolabeled antibodies can also be prepared using well-known techniques. See e.g., Junghans et al. in Cancer Chemotherapy and Biotherapy 655-686 (2d edition, Chafner and Longo, eds., Lippincott Raven (1996)). See also U.S. Patent Nos. 4,681 ,581 , 4,735,210, 5,101 ,827, 5,102,990 (Re. 35,500), 5,648,471 , and 5,697,902.
  • Antibodies employed in the invention preferably possess very high affinities, typically possessing Kds of from about 10 ⁇ 9 through about 10 "11 M, when measured by either solid phase or solution phase.
  • Antibodies used in the present invention can be expressed in cell lines other than hybridoma cell lines. Sequences encoding the cDNAs or genomic clones for the particular antibodies can be used for transformation of suitable mammalian or nonmammalian host cells. Transformation can be by any known method for introducing polynucleotides into a host cell, including, for example packaging the polynucleotide in a virus (or into a viral vector) and transducing a host cell with the virus (or vector) or by transfection procedures known in the art, as exemplified by U.S. Patent Nos. 4,399,216, 4,912,040, 4,740,461 , and 4,959,455.
  • Methods for introduction of heterologous polynucleotides into mammalian cells include, but are not limited to, dextran-mediated transfection, calcium phosphate precipitation, polybrene mediated transfection, protoplast fusion, electroporation, particle bombardment, encapsulation of the polynucleotide(s) in liposomes, peptide conjugates, dendrimers, and direct microinjection of the DNA into nuclei.
  • Mammalian cell lines available as hosts for expression are well known in the art and include many immortalized cell lines available from the American Type Culture Collection (ATCC), including but not limited to Chinese hamster ovary (CHO) cells, NSO 0 , HeLa cells, baby hamster kidney (BHK) cells, monkey kidney cells (COS), and human hepatocellular carcinoma cells (e.g., Hep G2).
  • ATCC American Type Culture Collection
  • Non-mammaiian cells can also be employed, including bacterial, yeast, insect, and plant cells.
  • Site directed mutagenesis of the antibody CH2 domain to eliminate glycosylation may be preferred in order to prevent changes in either the immunogenicity, pharmacokinetic, and/or effector functions resulting from non-human glycosylation.
  • the glutamine synthase system of expression is discussed in whole or part in connection with European Patent Nos. 0 216 846, 0 256 055, and 0 323 997, and European Patent Application No. 89303964.4.
  • Antibodies for use in the invention can also be produced transgenically through the generation of a mammal or plant that is transgenic for the immunoglobulin heavy and light chain sequences of interest and production of the antibody in a recoverable form therefrom.
  • Transgenic antibodies can be produced in, and recovered from, the milk of goats, cows, or other mammals. See, e.g., U.S. Patent Nos. 5,827,690, 5,756,687, 5,750,172, and 5,741 ,957. '
  • Non-Hematoloqic Malignancies Patients with advanced-stage non-hematologic malignancies (measurable disease defined by at least one lesion that can be accurately measured and whose size is >2 cm x 1 cm by conventional computed tomography (CT) scan or >1 cm x 1 cm by spiral CT scan) received a standard dose of docetaxel (TAXOTERE) (up to 75 mg/m 2 , using actual body weight to calculate body surface area (BSA)) by intravenous (IV) infusion over 1 hour on Day 1 only of each cycle. After the docetaxel infusion was completed, anti-IGF-1 R antibodies as described herein were administered intravenously in a 5 mg/ml liquid formulation at a dose between 0.1 mg/kg and 10 mg/kg.
  • CT computed tomography
  • BSA body surface area
  • the treatment regimen was repeated after 21 days, with escalation of the anti-IGF-1 R antibody dose, and every 21 days thereafter until disease progression or unacceptable toxicity develops for a minimum of 2 cycles and a maximum of 17 cycles.
  • the pre-medication regimen for docetaxel included oral dexamethasone 8 mg twice daily for three days starting one day prior to docetaxel administration. Prophylactic anti ⁇ emetics were provided as appropriate.
  • Dose escalation used an accelerated titration design utilizing a dose-doubling schema with 3-6 subjects per dose level (cohort). Within each new cohort there was no required waiting period between subjects. Subsequent cohorts were not opened until, the first subject at the current dose level had been observed for 21 days and subsequent subjects had been observed for 14 days.
  • anti-IGF-1 R antibodies as described herein were administered intravenously in a 5 mg/ml formulation at a dose between 0.05 mg/kg and 10 mg/kg.
  • the treatment regimen was repeated after 21 days, with escalation of the anti-IGF-1 R antibody dose, and every 21 days thereafter until disease progression or unacceptable toxicity develops, for a minimum of 1 cycle and a maximum of 6 cycles.
  • Doses were escalated using an accelerated titration design utilizing a dose-doubling schema with 3-6 subjects per cohort. Within each new cohort there was no required waiting period between subjects. Subsequent cohorts were not opened until the first subject at the current dose level has been observed for 21 days and subsequent subjects have been observed for 14 days.
  • Part 2 of the study is a two-arm randomized, non-comparative study of anti-IGF-1 R antibody in combination with paclitaxel and carboplatin (Arm A) and of paclitaxel and carboplatin alone (Arm B).
  • Arm A the patients in both arms are given the same dosages of paclitaxel and carboplatin, over the same time periods, as in the first part.
  • Arm B the same anti-IGF-1 R antibody dose they were given in Part 1.
  • the dose is determined in view of the safety and tolerability demonstrated in Part 1.
  • the treatment is repeated after 21 days, and every 21 days thereafter, until progression or unacceptable toxicity occurs for a minimum of 2 cycles and a maximum of 6.
  • PK parameters of the anti-IGF-1 R antibody The following endpoints are measured: PK parameters of the anti-IGF-1 R antibody, HAHA, response rate and time to progression, CTC, circulating IGF-1 , IGFBPs, and soluble circulating IGF-1 R.
  • Patients having metastatic breast cancer with at least one lesion that can be accurately measured in two dimensions and whose size is >2 cm x 1 cm by conventional CT scan or >1 cm x 1 cm by spiral CT scan are given epirubicin 75 mg/m 2 as a single 15 minute infusion.
  • docetaxel (TAXOTERE) 75 mg/m 2 is administered as a single IV infusion, followed by IV infusion of anti-IGF-1 R antibodies as described herein at a dose between 0.05 mg/kg and 10 mg/kg.
  • Prophylactic anti-emetics are given as appropriate.
  • the treatment is repeated after 21 days with escalation of the anti-IGF-1 R antibody dose, and every 21 days thereafter until disease progression or unacceptable toxicity develops for a minimum of 2 cycles and a maximum of 6.
  • Doses are escalated using an accelerated titration design utilizing a dose-doubling schema with 3-6 subjects per cohort. Within each new cohort there is no required waiting period between subjects. Subsequent cohorts may not be opened until the first subject at the current dose level has been observed for 21 days and subsequent subjects have been observed for 14 days.
  • PK parameters PK parameters
  • HAHA response rate
  • time to progression are calculated using the Kaplan-Meier product limit method.
  • Subjects are patients with metastatic adenocarcinoma of the prostate who, after at least one hormonal treatment (orchiectomy, estrogens, LHRH therapy, etc.), have testosterone levels less than 50 ng/dL, prostate-specific antigen (PSA) above 20 ng/mL, and an increase in PSA > 50% over nadir value on hormonal therapy measured on 3 successive occasions at least 1 week apart.
  • a pre-medication regimen for docetaxel includes oral dexamethasone 8 mg twice a day given for 3 days starting one day prior to docetaxel administration .
  • a 75 mg/m 2 dose of docetaxel (TAXOTERE) (using actual body weight to calculate BSA) is administered by IV infusion over 1 hour on Day 1 only of each cycle.
  • anti-IGF-1 R antibodies as described herein are administered intravenously in a 5 mg/ml liquid formulation.
  • Prednisone is given daily in two oral 5 mg doses per day, starting on Day 1.
  • Prophylactic anti-emetics may be given as appropriate.
  • the treatment regimen is repeated every 21 days ( ⁇ 3 days) until disease progression or unacceptable toxicity develops, for a maximum of 10 cycles.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention relates to a therapeutic method for the treatment of non-hematologic malignancies comprising administering anti-IGF-1R antibodies, particularly human anti-IGF-1R antibodies, to a patient, in conjunction with the administration of at least one other therapeutic agent. The invention further relates to pharmaceutical compositions comprising these antibodies and methods of using such compositions thereof for treatment.

Description

COMBINATION TREATMENT FOR NON-HEMATOLOGIC MALIGNANCIES USING AN ANTI-IGF-IR ANTIBODY
Background of the Invention
The present invention relates to a method of treatment for non-hematologic malignancies comprising the administration of anti-insulin-like growth factor I receptor (IGF- 1 R) antibodies, in conjunction with other therapeutic agents such as chemotherapeutic agents and hormonal therapy.
The insulin-like growth factor (IGF) signaling system plays an important role in the growth and development of many tissues and regulates overall growth. Insulin-like growth factor (IGF-1) is a 7.5-kD polypeptide that circulates in plasma in high concentrations and is detectable in most tissues. IGF-1 stimulates cell differentiation and cell proliferation, and is required by most mammalian cell types for sustained proliferation. These cell types include, among others, human diploid fibroblasts, epithelial cells, smooth muscle cells, T lymphocytes, neural cells, myeloid cells, chondrocytes, osteoblasts and bone marrow stem cells.
The first step in the transduction pathway leading to IGF-1 -stimulated cellular proliferation or differentiation is binding of IGF-1 or IGF-2 (or insulin at supraphysiological concentrations) to the IGF-1 receptor. The IGF-1 receptor (IGF-1 R) is composed of two types of subunits: an alpha subunit (a 130-135 kD protein that is entirely extracellular and functions in ligand binding) and a beta subunit (a 95-kD transmembrane protein, with transmembrane and cytoplasmic domains). IGF binding proteins (IGFBPs) have growth inhibiting effects by, at least in part, competitively binding IGFs and preventing their association with IGF-1 F. The interactions between IGF-1 , IGF-2, IGF1 R, and IGFBPs affect many physiological and pathological processes such as development, growth and metabolic regulation.
The IGF-1 R is initially synthesized as a single chain proreceptor polypeptide that is processed by glycosylation, proteolytic cleavage, and covalent bonding to assemble into a mature 460-kD heterotetramer comprising two alpha-subunits and two beta-subunits. The beta subunit(s) possesses ligand-activated tyrosine kinase activity. This activity is implicated in the signaling pathways mediating ligand action which involve autophosphorylation of the beta-subunit and phosphorylation of IGF-1 R substrates.
There is considerable evidence for a role for IGF-1 and/or IGF-1 R in the maintenance of tumor cells in vitro and in vivo. IGF-1 R levels are elevated in tumors of lung (Kaiser et al.,
J. Cancer Res. CHn. Oncol. 119: 665-668, 1993; Moody et al., Life Sciences 52: 1161-1173,
1993; Macauley et al., Cancer Res., 50: 2511-2517, 1990), breast (Pollack et al., Cancer Lett.
38: 223-230, 1987; Foekens et al., Cancer Res. 49: 7002-7009, 1989; Cullen et al., Cancer
Res. 49: 7002-7009, 1990; Arteaga et al., J. Clin. Invest. 84: 1418-1423, 1989), prostate and colon (Remaole-Bennet et al., J. CHn. Endocrinol. Metab. 75: 609-616, 1992; Guo et al.,
Gastroenterol. 102: 1101-1108, 1992). In addition, IGF-1 appears to be an autocrine stimulator of human gliomas (Sandberg-Nordqvist et al., Cancer Res. 53: 2475-2478, 1993), while IGF-1 stimulated the growth of fibrosarcomas that overexpressed IGF-1R (Butler et al., Cancer Res. 58: 3021-27, 1998). In addition, individuals with "high normal" levels of IGF-1 have an increased risk of common cancers compared to individuals with IGF-1 levels in the "low normal" range (Rosen et al., Trends Endocrinol. Metab. 10: 136-41 , 1999). For a review of the role IGF-1/IGF-1 receptor interaction plays in the growth of a variety of human tumors, see Macaulay, Br. J. Cancer, 65: 311-320, 1992.
Numerous classes of antineoplastic agents are currently in use. Docetaxel, one of a group of drugs called "taxanes," which are derived from the bark and needles of yew trees, is the first anticancer agent to show a significantly higher response rate than doxorubicin, a very active agent and widely used chemotherapy in the first-line treatment of metastatic breast cancer. Docetaxel also is the first chemotherapy drug as a single agent to demonstrate increased survival among patients with advanced breast cancer compared to the combination of mitomycin C and vinblastine, a commonly used regimen in this patient population. Median time to progression and time to treatment failure were significantly longer for docetaxel than for mitomycin C in combination with vinblastine, and the one-year survival rate significantly greater. Promising results have also been recorded for docetaxel in other human malignancies, such as ovarian, lung, head and neck, gastric and pancreatic cancers.
Paclitaxel, also a taxane, binds to microtubules and prevents their molecular disassembly, thereby inhibiting mitosis (cell division). With the spindle still in place the cell cannot divide into daughter cells. Paclitaxel is most effective against ovarian carcinomas and advanced breast carcinomas.
Hormonal therapy can be very effective in lowering the risk of recurrence for women with hormone-receptor-positive breast cancer. Tamoxifen is the hormonal therapy that has been around the longest — nearly 30 years. It blocks the effect of estrogen on breast cancer cells, keeping the cells from growing. Tamoxifen can reduce recurrence by 40-50% in post¬ menopausal women, and by 30-50% in pre-menopausal women. It also lowers the risk of a new breast cancer developing in the unaffected breast, and can slow down the progression of advanced disease.
In recent years, aromatase inhibitors have been used as hormonal therapy. This type of therapy is recommended only for postmenopausal women with hormone-receptor-positive breast cancer. It works by blocking the production of estrogen in muscle and fat tissue, which is the main source of estrogen in women beyond menopause, after which the ovaries stop making significant levels of estrogen.
Prostate cancer is the most common cancer and the second cause of cancer death in men in the United States. About 10% of the initial cases of prostate cancer present with metastatic disease. However, in the rest, metastases will develop despite treatment with surgery, radiation or medical therapy, and those metastases will eventually become refractory to hormonal treatment. The use of chemotherapy in hormone refractory (androgen independent) progressive prostate cancer (HRPC) has been characterized historically by poor efficacy and high toxicity. Newer regimens containing docetaxel have shown a survival benefit over previous palliative regimens. Despite this positive trend, the median survival of HRPC patients treated with docetaxel and prednisone is only 18.9 months; clearly, more effective regimens are required for the treatment of HRPC patients.
Although some currently available anti-cancer treatments have been successful, complete responses to these treatments are infrequently observed, and the patient population refractory to these treatments is still large. Thus, development of new therapeutic regimens, particularly those capable of augmenting or potentiating the anti-tumor activity of other anti¬ neoplastic agents, is necessary.
In view of the roles that IGF-1 and IGF-1 R have in such disorders as cancer and other proliferative disorders when IGF-1 and/or IGF-1 R are overexpressed, antibodies to IGF- 1 R have been produced that block binding of IGF-1 or IGF-2 to IGF-1 R. Such antibodies are described, for example, in International Patent Application No. WO 02/053596, published July 11 , 2002; International Patent Application Nos. WO 05/016967 and WO 05/016970, both published February 24, 2005; International Patent Application No. WO 03/106621 , published December 24, 2003; International Patent Application No. WO 04/083248, published September 30, 2004; International Patent Application No. WO 03/100008, published December 4, 2003; International Patent Publication WO 04/087756, published October 14, 2004; and International Patent Application No WO 05/005635, published January 26, 2005. Because of their ability to block a tumor cell survival pathway, it is desirable to use such anti- IGF-1R antibodies to treat cancer, particularly non-hematological malignancies, in patients to obtain an improved clinical benefit relative to standard cancer treatment regimes alone. Summary of the Invention
The present invention is directed to a method for the treatment of an advanced non- hematologic malignancy in a patient in need of such treatment comprising the step of administering to the patient a therapeutically effective amount of an anti-IGF-1 R antibody.
More particularly, the present invention is directed to a method comprising the step of administering to the patient an antibody that specifically binds to IGF-1 R in combination with a therapeutically effective amount of at least one agent selected from the group consisting of an alkylating agent, a folate antagonist, a pyrimidine antagonist, a cytotoxic antibiotic, a platinum compound, a taxane, a vinca alkaloid, a topoisomerase inhibitor, an EGFR inhibitor, and a hormonal therapy agent. Preferably the antibody is one that specifically binds to human IGF- 1 R. -A-
In a preferred embodiment of the present invention, the anti-lGF-1 R antibody has the following properties: (a) a binding affinity for human IGF-1 R of Kd of 8 x 10"9 or less, and (b) inhibition of binding between human IGF-1 R and IGF-1 with an IC50 of less than 100 nM.
In another preferred embodiment of the present invention, the anti-IGF-1 R antibody comprises (a) a heavy chain comprising the amino acid sequences of CDR-1 , CDR-2, and CDR-3 of an antibody selected from the group consisting of 2.12.1 , 2.13.2, 2.14.3, 4.9.2, 4.17.3, and 6.1.1 , and (b) a light chain comprising the amino acid sequences of CDR-1 , CDR- 2, and CDR-3 of an antibody selected from the group consisting of 2.12.1 , 2.13.2, 2.14.3, 4.9.2, 4.17.3, and 6.1.1 , or (c) sequences having changes from the CDR sequences of an antibody selected from the group consisting of 2.12.1 , 2.13.2, 2.14.3, 4.9.2, 4.17.3, and 6.1.1 , said sequences being selected from the group consisting of conservative changes, wherein the conservative changes are selected from the group consisting of replacement of nonpolar residues by other nonpolar residues, replacement of polar charged residues by other polar uncharged residues, replacement of polar charged residues by other polar charged residues, and substitution of structurally similar residues; and non-conservative substitutions, wherein the non-conservative substitutions are selected from the group consisting of substitution of polar charged residue for polar uncharged residues and substitution of nonpolar residues for polar residues, additions and deletions.
The present invention is also directed to a pharmaceutical composition for the treatment of a non-hematologic malignancy comprising (a) a therapeutically effective amount of an antibody that specifically binds IGF-1 R, (b) a therapeutically effective amount of at least one agent selected from the group consisting of an alkylating agent, a folate antagonist, a pyrimidine antagonist, a cytotoxic antibiotic, a platinum compound, a taxane, a vinca alkaloid, a topoisomerase1 inhibitor, an EGFR inhibitor, and a hormonal therapy agent; and (c) a pharmaceutically acceptable carrier. Detailed Description Of The Drawings
Figs. 1A-1C show alignments of the nucleotide sequences of the light chain variable regions from six human anti-IGF-1 R antibodies to each other and to germline sequences. Fig. 1A shows the alignment of the, nucleotide sequences of the variable region of the light chain (VL) of antibodies 2.12.1 (SEQ ID NO: 1 ) 2.13.2 (SEQ ID NO: 5),,2.14.3 (SEQ ID NO: 9) and 4.9.2 (SEQ ID NO: 13) to each other and to the germline V/c A30 sequence (SEQ ID NO: 39). Fig. 1 B shows the alignment of the nucleotide sequence of VL of antibody 4.17.3 (SEQ ID NO: 17) to the germline V/c 012 sequence (SEQ ID NO: 41). Fig. 1C shows the alignment of the nucleotide sequence of VL of antibody 6.1.1 (SEQ ID NO: 21 ) to the germline V/c A27 sequence (SEQ ID NO: 37). The alignments also show the CDR regions of the VL from each antibody. The consensus sequences for Figs. 1A-1C are shown in SEQ ID NOS: 53-55, respectively. Figs. 2A-2D show alignments of the nucleotide sequences of the heavy chain variable regions from six human anti-IGF-1 R antibodies to each other and to germline sequences. Fig. 2A shows the alignment of the nucleotide sequence of the VH of antibody 2.12.1 (SEQ ID NO: 3) to the germline VH DP-35 sequence (SEQ ID NO: 29). Fig. 2B shows the alignment of the nucleotide sequence of the VH of antibody 2.14.3 (SEQ ID NO: 11) to the germline VIV- 4/4.35 sequence (SEQ ID NO: 43). Figs. 2C-1 and 2C-2 show the alignments of the nucleotide sequences of the VH of antibodies 2.13.2 (SEQ ID NO: 7), 4.9.2 (SEQ ID NO: 15) and 6.1.1 (SEQ ID NO: 23) to each other and to the germline VH DP-47 sequence (SEQ ID NO: 31). Fig. 2D shows the alignment of the nucleotide sequence of the VH of antibody 4.17.3 (SEQ ID NO: 19) to the germline VH DP-71 sequence (SEQ ID NO: 35). The alignment also shows the CDR regions of the antibodies. The consensus sequences for Figs. 2A-2D are shown in SEQ ID NOS: 56-59, respectively.
Fig. 3A shows the number of mutations in different regions of the heavy and light chains of 2.13.2 and 2.12.1 compared to the germline sequences. Figs. 3A-D show alignments of the amino acid sequences from the heavy and light chains of antibodies 2.13.2 and 2.12.1 with the germline sequences from which they are derived. Fig. 3B shows an alignment of the amino acid sequence of the heavy chain of antibody 2.13.2 (SEQ ID NO: 45) with that of germline sequence DP-47(3-23)/D6-19/JH6 (SEQ ID NO: 46). Fig. 3C shows an alignment of the amino acid sequence of the light chain of antibody 2.13.2 (SEQ ID NO: 47) with that of germline sequence A30/Jk2 (SEQ ID NO: 48). Fig. 3D shows an alignment of the amino acid sequence of the heavy chain of antibody 2.12.1 (SEQ ID NO: 49) with that of germline sequence DP-35(3-11 )/D3-3/JH6 (SEQ ID NO: 50). Fig. 3E shows an alignment of the amino acid sequence of the light chain of antibody 2.12.1 (SEQ ID NO: 51 ) with that of germline sequence A30/Jk1 (SEQ ID NO: 52). For Figures 3B-E, the signal sequences are in italic, the CDRs are underlined, the constant domains are bold, the framework (FR) mutations are highlighted with a plus sign ("+") above the amino acid residue and CDR mutations are highlighted with an asterisk above the amino acid residue.
Figure 4 shows that anti-IGF-1 R antibodies 2.13.2 and 4.9.2 reduce IGF-1 R phosphotyrosine signal in 3T3-IGF-1 R tumors. Figure 5 shows that anti-IGF-1 R antibody 2.13.2 inhibits 3T3-IGF-1 R tumor growth in vivo.
Detailed Description of the Invention
The present invention are directed to the treatment of non-hematologic malignancies, including breast, lung, brain, skin, ovarian, prostate, head and neck, colorectal, gastric, bladder, renal, esophageal, and pancreatic cancers, as well as solid tumors of childhood. Treatment of both early stage and advanced (metastatic) cancers are within the scope of the present invention. In preferred embodiments, the method of the present invention is used in the treatment of breast cancer, prostate cancer, and non-small cell lung cancer (NSCLC).
There are many classes of chemotherapeutic drugs currently in use for the treatment of non-hematological malignancies that are suitable for use in the combination therapy of the present invention. For example, alkylating agents are a class of drugs that alkylate DNA, restricting uncoiling and replication of strands. Alkylating agents include cyclophosphamide (CYTOXAN), ifosfamide (IFEX), mechlorethamine hydrochloride (MUSTARGEN), thiotepa (THIOPLEX), streptozotocin (ZANOSAR), carmustine (BICNU, GLIADEL WAFER), lomustine (CEENU), and dacarbazine (DTIC-DOME). A preferred alkylating agent for use in the methods of the present invention is cyclophosphamide.
Folate antagonists bind to dihydrofolate reductase (DHFR) and interfere with pyrimidine (thymidine) synthesis. Methotrexate (MATREX, FOLEX, TREXALL), trimetrexate (NEUTREXIN) and pemetrexed (ARIMTA) are folate antagonists suitable for use in the methods of the present invention. In addition to DHFR, pemetrexed also inhibits thymidylate synthase and glycinamide ribonucleotide formyl transferase, two other folate-dependent enzymes involved in thymidine synthesis.
Pyrimidine antagonists inhibit enzymes involved in pyrimidine synthesis. As pyrimidine analogs, they also interfere with DNA production by competing with normal nucleotides for incorporation into the DNA molecule. Pyrimidine antagonists suitable for use in the methods of the present invention include 5-fluorouracil (5-FU); capecitabine (XELODA), a prodrug of 5'-deoxy-5-fluorouridine (5'-FDUR), which is enzymatically converted to 5-FU in vivo; raltitrexed (TOMUDEX); tegafur-uracil (UFTORAL); and gemcitabine (GEMZAR).
Anthracycline antibiotics exert a cytotoxic effect by inhibiting the uncoiling of DNA by intercalation between DNA strands. Anthracyclines and anthracyclines derivatives include doxorubicin hydrochloride (ADRIAMYCIN, RUBEX, DOXIL), epirubicin hydrochloride (ELLENCE, PHARMORUBICIN), daunorubicin (CERUBIDINE, DAUNOXOME), nemorubicin, idarubicin hydrochloride (IDAMYCIN PFS, ZAVEDOS) and mitoxantrone (DHAD, NOVANTRONE). Preferred anthracyclines for use with the present invention include doxorubicin and epirubicin. Other cytotoxic antibiotics are useful as cancer chemotherapeutic agents and suitable for use in the present invention. These include dactinomycin (actinomycin D, COSMEGEN), plicamycin (MITHRACIN), mitomycin (MUTAMYCIN), and bleomycin (BLENOXANE). Dactinomycin is particularly preferred.
Platinum compounds exert their anti-neoplastic effect by intercalation and intracalation between DNA strands, which inhibits uncoiling of the DNA. Platinum compounds useful in the methods of the present invention include cisplatin (PLATINOL) and carboplatin (PARAPLATIN). Taxanes promote assembly of microtubules while inhibiting their disassembly into tubulin, thereby blocking a cell's ability to break down the mitotic spindle during mitosis. They have demonstrated significant activity against many solid tumors as single agent therapy and in combination with other chemotherapy agents. One embodiment of the combination therapy of the present invention includes the use of one or more taxanes in combination with the IGF- 1 R antibody. Suitable taxanes for use in combination with the IGF-1 R antibody include docetaxel (TAXOTERE) and paciitaxel (TAXOL).
Vinca alkaloids, like taxanes, are "spindle poisons," acting on the microtubules that form the mitotic spindle. They inhibit mitosis by interfering with microtubule assembly, keeping the spindle from being formed. Vinca alkaloids include vindesine (ELDISINE), vinblastine sulfate (VELBAN), vincristine sulfate (ONCOVIN) and vinorelbine tartrate (NAVELBINE). A preferred vinca alkaloid for use in the methods of the present invention is vinorelbine.
The camptothecin analogs act through inhibition of topoisomerase I, an enzyme critical for DNA replication and packaging. Levels of topoisomerase I are higher in tumor cells than in normal tissue. Camptothecin analogs useful in the methods of the present invention. include irinotecan (CAMPTOSAR) and topotecan (HYCAMTIN). lrinotecan is particularly preferred.
Inhibitors of topoisomerase Il interfere with the normal DNA breakage resealing process (as do inhibitors of topoisomerase I), and they also interfere with the separation of newly replicated chromosomes, resulting in clastogenic mutation and potential cell death.
The anthracyline antibiotics discussed above exhibit topoisomerase Il inhibitory activity.
Derivatives of podophyllotoxin, an extract of the mayapple that is an antimitotic glucoside) are also topoisomerase Il inhibitors. Podophyllotoxin derivatives suitable for use in the present invention include etoposide (VEPESID), etoposide phosphate (ETOPOPHOS), and teniposide
(VUMON). Etoposide is particularly preferred.
Compounds directed at inhibition of epidermal growth factor receptor (EGFR) tyrosine kinase (TK) represent a relatively new class of antineoplastic drugs that are useful in the method of the present invention. Many human cancers express members of the EGFR family on the cell surface. When a ligand binds to EGFR, it sets off a cascade of cellular reactions that result in increased cell division and influence other aspects of cancer development and progression, including angiogenesis, metastatic spread, and inhibition of apoptosis. EGFR- TK inhibitors may selectively target one of the members of the EGFR family (EGFR (also known as HER1 or ErbB-1), HER2/neu (also known as ErbB-2), HER3 (also known as ErbB- 3), or HER4 (also known as ErbB-4)), or may target two or more of them. EGFR-TK inhibitors suitable for use in the present invention include gefitinib (IRESSA), erlotinib (TARCEVA), trastuzumab (HERCEPTIN), panitumumab (ABX-EGF; Abgenix/Amgen), lapatinib (GlaxoSmithKline), CI-1033 (Pfizer), GW2016 (GlaxoSmithKline), EKB-569 (Wyeth), PKI-166 (Novartis), CP-724,714 (Pfizer), and BIBX-1382 (Boeringer-lngelheim). Additional EGFR-TK inhibitors are described in United States Patent Publication No. US 2002-0169165A1 , published November 14, 2002. Another embodiment of the combination therapy of the present invention includes the use of hormonal therapy in combination with the IGF-1 R antibody, particularly anti-estrogens in the treatment of breast cancer. Some hormonal treatments compete with estrogen for binding sites in breast tissue. These include tamoxifen citrate (NOLVADEX) and fulvestrant (FASLODEX). Similarly, anti-androgens block testosterone receptors and therefore are useful in the treatment of androgen-dependent prostate cancer.
Other hormone treatments include aromatase inhibitors. This class of hormonal agents inactivate aromatase, the enzyme which converts androgens to estrogens. Examples of aromatase inhibitors suitable for use in combination with the IGF-1 R antibody include anastrozole (ARIMIDEX), letrozole (FEMARA), exemestane (AROMASIN), and fadrozole hydrochloride. Exemestane is a particularly preferred aromatase inhibitor for use in the methods of the present invention.
Co-administration of the antibody with an additional therapeutic agent (combination therapy) encompasses administering a pharmaceutical composition comprising both the anti- IGF-1 R antibody and one or more additional therapeutic agents, and administering two or more separate pharmaceutical compositions, one comprising the anti-IGF-1 R antibody and the other(s) comprising the additional therapeutic agent(s). Further, although co¬ administration or combination (conjoint) therapy generally mean that the antibody and additional therapeutic agents are administered at the same time as one another, it also encompasses simultaneous, sequential or separate dosing of the individual components of the treatment.
The present invention also encompasses the administration of other therapeutic agents in addition to the first and second components, either concurrently with one or more of those components, or sequentially. Such therapeutic agents include analgesics, cancer vaccines, anti-vascular agents, anti-proliferative agents, and anti-emetic agents. Preferred anti-emetic agents include aprepitant, ondansetron hydrochloride, granisetron hydrochloride, and metoclopramide.
Each administration may vary in its duration from a rapid administration to a continuous perfusion. As a result, for the purposes of the present invention, the combinations are not exclusively limited to those that are obtained by physical association of the constituents, but also to those that permit a separate administration, which can be simultaneous or spaced out over a period of time. The compositions according to the invention are preferably compositions which can be administered parentally. However, these compositions may be administered orally or intraperitoneal^ in the case of localized regional therapies.
As will be appreciated by one of skill in the art, the choice of therapeutic agents to be used in combination with IGF-1 R antibodies, and the timing of their use, will be determined in part by the type and stage of the cancer that is being treated. For example, in early breast cancer (where the cancer has not spread outside the breast), surgery and radiation are generally followed by adjuvant chemotherapy or adjuvant hormonal therapy, either of which may be combined with IGF-1R antibodies in the methods of the present invention. Typical adjuvant chemotherapy for early breast cancer includes cyclophosphamide, methotrexate and 5-FU ("CMF"); 5-FU, doxorubicin, and cyclophosphamide ("FAC"); docetaxel, doxorubicin, and cyclophosphamide ("TAG"); doxorubicin and cyclophosphamide ("AC"); doxorubicin and cyclophosphamide followed by paclitaxel ("AC and T"); and 5-FU, epirubicin, and cyclophosphamide ("FEC"). Tamoxifen is a preferred hormonal treatment at this stage.
In locally advanced breast cancer, wherein the cancer has spread only to nearby tissues or lymph nodes, the patient is often given chemotherapy prior to surgery and radiation, which are then followed by adjuvant hormonal therapy. Alternatively, surgery/radiation is followed by adjuvant chemotherapy, then adjuvant hormonal therapy. IGF-1R antibodies may be administered in conjunction with the chemotherapeutic or hormonal therapy agents whether they are used either before or after surgery/radiation. Typical chemotherapy regimes for locally advanced breast cancer include FAC, AC, FEC, and doxorubicin plus docetaxel ("AT").
Metastatic breast cancer has spread to other parts of the body from the breast in which it started. Chemotherapy optionally may be preceded by hormonal therapy. First line hormonal therapy currently includes tamoxifen and anastrozole. First line chemotherapy regimens currently include FAC, TAC, docetaxel plus epirubicin, docetaxel, paclitaxel, capecitabine, vinorelbine, and trastuzumab. Second line chemotherapy treatments include docetaxel, alone or in combination with capecitabine. The methods of the present invention are suitable for use both as first line therapy and second line therapy.
In the United States, the combination of paclitaxel and carboplatin has become accepted as the standard of care for first line treatment of inoperable Stage IHB (i.e. cancer has spread to structures near the lung, to lymph nodes in the mediastinum, or to lymph nodes on the other side of the chest or in the lower neck) and Stage IV (i.e. cancer has spread to other parts of the body or to another lobe of the lungs) non-small cell lung cancer (NSCLC). But the overall response rate is only approximately 28% for patients with performance status 0-1 in efficacy studies with a predominantly Stage IV population. In Europe, first line treatment for NSCLC is gemcitabine and cisplatin. Other treatment regimens for NSCLC include paclitaxel alone or with cisplatin or gemcitabine; docetaxel alone or with cisplatin or gemcitabine; vinorelbine alone or with gemcitabine; irinotecan alone or with gemcitabine; pemetrexed; and gefitinib.
It is known that signaling through IGF-1 R is required for the tumorgenicity of cell lines and has been shown to decrease the cytotoxicity of chemotherapy, and that blocking IGF-1 R activity enhances the effectiveness of current therapies and prevents tumor progression in animal models. It was therefore expected that an inhibitor of IGF-1 R such as the antibodies of the present invention would reduce tumor cell survival and enhance the efficacy of chemotherapy when given in combination.
When incubated with cells, fully human monoclonal antibodies that are highly specific and potent inhibitors of IGF-1 -induced receptor autophosphorylation induced down-regulation of IGF-1 R by receptor internalization. The doses that down-regulated IGF-1 R in solid tumor ex vivo models (31.25-125 μg) corresponded to antibody concentrations of 8-40 μg/ml at Day 1 and 2-20 μg/ml at Day 9. Intraperitoneal administration of the anti-IGF-1R antibodies to athymic mice bearing tumors of the transfectant IGF-1 R over-expressing NIH-3T3 cell line resulted in a dose dependent inhibition of tumor growth. The serum concentration of anti- IGF-1 R antibodies that led to 50% growth inhibition was 20 μg/ml at Day 1 , and 13 μg/ml at Day 9. Similar anti-tumor studies were extended to human tumor xenograft models. As a single agent, anti-IGF-1 R antibodies inhibited the growth of several xenograft models including breast, lung and colorectal carcinomas. The combination of anti-IGF-1 R antibodies with paclitaxel or carboplatin was tested in the H460 and EBC-1 human NSCLC tumor xenograft models. Combination of anti-IGF-1 R antibodies with those agents increased their tumor growth inhibition compared to each agent alone.
Unless otherwise defined herein, scientific, technical, and medical terms used in connection with the present invention shall have the meanings that are commonly understood by those of ordinary skill in the art. Generally, nomenclatures used in connection with, and techniques of, cell and tissue culture, molecular biology, immunology, microbiology, genetics and protein and nucleic acid chemistry described herein are those well known and commonly used in the art. The following terms, unless otherwise indicated, shall be understood to have the following meanings:
An "antibody" refers to an intact immunoglobulin or to an antigen-binding portion thereof that competes with the intact antibody for specific binding. Antigen-binding portions may be produced by recombinant DNA techniques or by enzymatic or chemical cleavage of intact antibodies. Antigen-binding portions include, inter alia, Fab, Fab', F(ab')2, Fv, dAb, and complementarity determining region (CDR) fragments, single-chain antibodies (scFv), chimeric antibodies, diabodies and polypeptides that contain at least a portion of an immunoglobulin that is sufficient to confer specific antigen binding to the polypeptide.
Immunoglobulin chains exhibit the same general structure of relatively conserved framework regions (FR) joined by three hypervariable regions, also called complementarity determining regions or CDRs. The CDRs from the two chains of each pair are aligned by the framework regions, enabling binding to a specific epitope. From N-terminus to C-terminus, both light and heavy chains comprise the domains FR1 , CDR1 , FR2, CDR2, FR3, CDR3 and FR4. The assignment of amino acids to each domain is in accordance with the definitions of Kabat, Sequences of Proteins of Immunological Interest (National Institutes of Health, Bethesda, Md. (1987 and 1991)), or Chothia & Lesk, J. MoI. Biol. 196:901-917 (1987); Chothia et al., Nature 342:878-883 (1989).
An "isolated antibody" is an antibody that (1) is not associated with naturally- associated components, including other naturally-associated antibodies, that accompany it in its native state, (2) is free of other proteins from the same species, (3) is expressed by a cell from a different species, or (4) does not occur in nature. Examples of isolated antibodies include an anti-IGF-1R antibody that has been affinity purified using IGF-1 R is an isolated antibody, an anti-IGF-1 R antibody that has been synthesized by a hybridoma or other cell line in vitro, and a human anti-IGF-1 R antibody derived from a transgenic mouse.
The term "chimeric antibody" refers to an antibody that contains one or more regions from one antibody and one or more regions from one or more other antibodjes. In a preferred embodiment, one or more of the CDRs are derived from a human anti-IGF-1 R antibody. In a more preferred embodiment, all of the CDRs are derived from a human anti-IGF-1 R antibody. In another preferred embodiment, the CDRs from more than one human anti-IGF-1 R antibodies are mixed and matched in a chimeric antibody. Further, the framework regions may be derived from one of the same anti-IGF-1 R antibodies, from one or more different antibodies, such as a human antibody, or from a humanized antibody.
The term "epitope" includes any protein determinant capable of specific binding to an immunoglobulin or T-cell receptor. Epitopic determinants usually consist of chemically active surface groupings of molecules such as amino acids or sugar sides chains and usually have specific three dimensional structural characteristics, as well as specific charge characteristics. An antibody is said to specifically bind an antigen when the dissociation constant is <1 μM, preferably < 100 nM and most preferably < 10 nM.
As applied to polypeptides, the term "substantial identity" means that two peptide sequences, when optimally aligned, such as by the programs GAP or BESTFIT using default gap weights, share at least 75% or 80% sequence identity, preferably at least 90% or 95% sequence identity, even more preferably at least 98% or 99% sequence identity. Preferably, residue positions that are not identical differ by conservative amino acid substitutions. A "conservative amino acid substitution" is one in which an amino acid residue is substituted by another amino acid residue having a side chain (R group) with similar chemical properties (e.g., charge or hydrophobicity). In general, a conservative amino acid substitution will not substantially change the functional properties of a protein. In cases where two or more amino acid sequences differ from each other by conservative substitutions, the percent sequence identity or degree of similarity may be adjusted upwards to correct for the conservative nature of the substitution. Means for making this adjustment are well-known to those of skill in the art. See, e.g., Pearson, Methods MoI. Biol. 24: 307-31 (1994). Examples of groups of amino acids that have side chains with similar chemical properties include 1 ) aliphatic side chains: glycine, alanine, valine, leucine and isoleucine; 2) aliphatic-hydroxyl side chains: serine and threonine; 3) amide-containing side chains: asparagine and glutamine; 4) aromatic side chains: phenylalanine, tyrosine, and tryptophan; 5) basic side chains: lysine, arginine, and histidine; and 6) sulfur-containing side chains are cysteine and methionine. Conservative amino acids substitution groups include: valine-leucine-isoleucine, phenylalanine-tyrosine, lysine-arginine, alanine-valine, glutamate-aspartate, and asparagine-glutamine.
Preferred amino acid substitutions are those which: (1 ) reduce susceptibility to proteolysis, (2) reduce susceptibility to oxidation, (3) alter binding affinity for forming protein complexes, (4) alter binding affinities, and (4) confer or modify other physicochemical or functional properties of such analogs. Analogs can include various mutations of a sequence other than the naturally-occurring peptide sequence. For example, single or multiple amino acid substitutions (preferably conservative amino acid substitutions) may be made in the naturally-occurring sequence (preferably in the portion of the polypeptide outside the domain(s) forming intermolecular contacts. A conservative amino acid substitution should not substantially change the structural characteristics of the parent sequence (e.g., a replacement amino acid should not tend to break a helix that occurs in the parent sequence, or disrupt other types of secondary structure that characterizes the parent sequence).
The phrase "in combination with" encompasses simultaneous, sequential or separate dosing of the individual components of the treatment. For example, the antibody may be administered once every three days, while the additional therapeutic agent is administered once daily. The antibody may be administered prior to or subsequent to treatment of the disorder with the additional therapeutic agent. Similarly, the anti-IGF-1R antibody may be administered prior to or subsequent to other therapy, such as radiotherapy, chemotherapy, photodynamic therapy, surgery or other immunotherapy.
The terms "concurrently" and "simultaneously" are used interchangeably and mean the compounds of the combination therapy of the present invention are administered (1 ) simultaneously in time, or (2) at different times during the course of a common treatment schedule. The term "sequentially" as used herein means administration of the a first component, followed by administration of a second component. Anti-IGF-1 R antibodies may be the first component or the second component. After administration of one component, the second component can be administered substantially immediately after the first component, or the second component can be administered an effective time period after the first component; the effective time period is the amount of time given for realization of maximum benefit from the administration of the first component.
The term "patient" includes mammals. In a preferred embodiment, the mammal is a human.
The term "treating," as used herein, unless otherwise indicated, means reversing, alleviating, inhibiting the progress of, or preventing the disorder or condition to which such term applies, or one or more symptoms of such disorder or condition. The term "treatment," as used herein, unless otherwise indicated, refers to the act of treating as "treating" is defined immediately above.
Human antibodies avoid certain of the problems associated with antibodies that possess mouse or rat variable and/or constant regions. More preferred are fully human anti- human IGF-1 R antibodies. Fully human anti-IGF-1R antibodies are expected to minimize the immunogenic and allergic responses intrinsic to mouse or mouse-derivatized monoclonal antibodies (Mabs) and thus to increase the efficacy and safety of the administered antibodies. The use of fully human antibodies can be expected to provide a substantial advantage in the treatment of chronic and recurring human diseases, such as inflammation and cancer, which may require repeated antibody administrations. In another embodiment, the invention provides an anti-IGF-1 R antibody that does not bind complement.
In another aspect of the invention, the anti-IGF-1 R antibodies bind to IGF-1 R with high affinity. In one embodiment, the anti-IGF-1 R antibody binds to IGF-1 R with a Kd of 1 x 10'8 M or less. In a more preferred embodiment, the antibody binds to IGF-1 R with a Kd or 1 x 10"9 M or less. In an even more preferred embodiment, the antibody binds to IGF-1 R with a Kd or 5 x 10'10 M or less. In another preferred embodiment, the antibody binds to IGF-1 R with a Kd or 1 x 10'10 M or less. In another preferred embodiment, the antibody binds to IGF-1 R with substantially the same Kd as an antibody selected from 2.12.1 , 2.13.2, 2.14.3, 3.1.1 , 4.9.2, 4.17.3 or 6.1.1. In another preferred embodiment, the antibody binds to IGF-1 R with substantially the same Kd as an antibody that comprises one or more CDRs from an antibody selected from 2.12.1 , 2.13.2, 2.14.3, 3.1.1 , 4.9.2, 4.17.3 or 6.1.1.
The invention also employs an anti-IGF-1 R antibody that binds the same antigen or epitope as a human anti-IGF-1 R antibody. The invention may also employ an anti-IGF-1 R antibody that cross-competes with a human anti-IGF-1 R antibody. In a preferred embodiment, the human anti-IGF-1 R antibody is 2.12.1 , 2.13.2, 2.14.3, 3.1.1 , 4.9.2, 4.17.3 or 6.1.1. In another preferred embodiment, the human anti-IGF-1 R comprises one or more CDRs from an antibody selected from 2.12.1 , 2.13.2, 2.14.3, 3.1.1 , 4.9.2, 4.17.3 or 6.1.1
The invention can also be practiced using an anti-IGF-1 R antibody that comprises variable sequences encoded by a human K gene. In a preferred embodiment, the variable sequences are encoded by either the V/c A27, A30 or 012 gene family. In a preferred embodiment, the variable sequences are encoded by a human V/c A30 gene family. In a more preferred embodiment, the light chain comprises no more than ten amino acid substitutions from the germline V/c A27, A30 or 012, preferably no more than six amino acid substitutions, and more preferably no more than three amino acid substitutions. In a preferred embodiment, the amino acid substitutions are conservative substitutions.
In a preferred embodiment, the VL of the anti-IGF-1 R antibody contains the same amino acid substitutions, relative to the germline amino acid sequence, as any one or more of the VL of antibodies 2.12.1 , 2.13.2, 2.14.3, 3.1.1 , 4.9.2, 4.17.3 or 6.1.1.
In another preferred embodiment, the light chain comprises an amino acid sequence that is the same as the amino acid sequence of the VL of 2.12.1 , 2.13.2, 2.14.3, 3.1.1 , 4.9.2, 4.17.3 or 6.1.1. In another highly preferred embodiment, the light chain comprises amino acid sequences that are the same as the CDR regions of the light chain of 2.12.1, 2.13.2, 2.14.3, 3.1.1 , 4.9.2, 4.17.3 or 6.1.1. In another preferred embodiment, the light chain comprises an amino acid sequence from at least one CDR region of the light chain of 2.12.1 , 2.13.2, 2.14.3, 3.1.1 , 4.9.2, 4.17.3 or 6.1.1.
The present invention can also be carried out using an anti-IGF-1 R antibody or portion thereof comprising a human heavy chain or a sequence derived from a human heavy chain. In one embodiment, the heavy chain amino acid sequence is derived from a human VH DP-35, DP-47, DP-70, DP-71 or VIV-4/4.35 gene family. In a preferred embodiment, the heavy chain amino acid sequence is derived from a human VH DP-47 gene family. In a more preferred embodiment, the heavy chain comprises no more than eight amino acid changes from germline VH DP-35, DP-47, DP-70, DP-71 or VIV-4/4.35, more preferably no more than six amino acid changes, and even more preferably no more than three amino acid changes.
In a preferred embodiment, the VH of the anti-IGF-1 R antibody contains the same amino acid substitutions, relative to the germline amino acid sequence, as any one or more of the VH of antibodies 2.12.1 , 2.13.2, 2.14.3, 3.1.1 , 4.9.2, 4.17.3 or 6.1.1. In another embodiment, the amino acid substitutions are made in the same position as those found in any one or more of the VH of antibodies 2.12.1 , 2.13.2, 2.14.3, 3.1.1 , 4.17.3., 4.9.2 or 6.1.1 , but conservative amino acid substitutions are made rather than using the same amino acid. In another preferred embodiment, the heavy chain comprises an amino acid sequence that is the same as the amino acid sequence of the VH of 2.12.1 , 2.13.2, 2.14.3, 3.1.1 , 4.9.2, 4.17.3 or 6.1.1. In another highly preferred embodiment, the heavy chain comprises amino acid sequences that are the same as the CDR regions of the heavy chain of 2.12.1 , 2.13.2, 2.14.3, 3.1.1, 4.9.2, 4.17.3 or 6.1.1. In another preferred embodiment, the heavy chain comprises an amino acid sequence from at least one CDR region of the heavy chain of 2.12.1 , 2.13.2, 2.14.3, 3.1.1 , 4.9.2, 4.17.3 or 6.1.1. In another preferred embodiment, the heavy chain comprises amino acid sequences from CDRs from different heavy chains. In a more preferred embodiment, the CDRs from different heavy chains are obtained from 2.12.1 , 2.13.2, 2.14.3, 3.1.1 , 4.9.2, 4.17.3 or 6.1.1.
In another embodiment, the invention employs an anti-IGF-1 R antibody that inhibits the binding of IGF-1 to IGF-1 R or the binding of IGF-2 to IGF-1 R. In a preferred embodiment, the IGF-1 R is human. In another preferred embodiment, the anti-IGF-1 R antibody is a human antibody. In another embodiment, the antibody or portion thereof inhibits binding between IGF-1 R and IGF-1 with an IC50 of no more than 100 nM. In a preferred embodiment, the IC50 is no more than 10 nM. In a more preferred embodiment, the IC50 is no more than 5 nM. The IC50 can be measured by any method known in the art. Typically, an IC50 can be measured by ELISA or RIA. In a preferred embodiment, the IC50 is measured by RIA.
In another embodiment, the invention employs an anti-IGF-1 R antibody that prevents activation of the IGF-1 R in the presence of IGF-i. In another aspect of the invention, the antibody causes the downregulation of IGF-1 R from a cell treated with the antibody. In a preferred embodiment, the antibody is selected 2.12.1 , 2.13.2, 2.14.3, 3.1.1 , 4.9.2, or 6.1.1 , or comprises a heavy chain, light chain or antigen-binding region thereof.
Human antibodies can be produced by immunizing a non-human animal comprising of some or all of the human immunoglobulin locus with an IGF-1 R antigen. In a preferred embodiment, the non-human animal is a XENOMOUSE™, which is an engineered mouse strain that comprises large fragments of the human immunoglobulin loci and is deficient in mouse antibody production. See, e.g., Green et al. Nature Genetics 7:13-21 (1994) and United States Patent Nos. 5,916,771, 5,939,598, 5,985,615, 5,998,209, 6,075,181 , 6,091 ,001 , 6,114,598, and 6,130,364. See also International Patent Application Nos. WO 91/10741 , published July 25, 1991 ; WO 94/02602, published February 3, 1994; WO 96/34096 and WO 96/33735, both published October 31 , 1996; WO 98/16654, published April 23, 1998; WO 98/24893, published June 11, 1998; WO 98/50433, published November 12, 1998; WO 99/45031 , published September 10, 1999; WO 99/53049, published October 21 , 1999; WO 00/09560, published February 24, 2000; and WO 00/037504, published June 29, 2000. The XENOMOUSE ™ produces an adult-like human repertoire of fully human antibodies, and generates antigen-specific human monoclonal antibodies. A second generation XENOMOUSE™ contains approximately 80% of the human antibody repertoire through introduction of megabase sized, germline configuration YAC fragments of the human heavy chain loci and K light chain loci. See Mendez et al. Nature Genetics 15:146-156 (1997), Green and Jakobovits J. Exp. Med. 188:483-495 (1998).
The IGF-1 R antigen can be administered with an adjuvant to stimulate the immune response. Such adjuvants include complete or incomplete Freund's adjuvant, RIBI (muramyl dipeptides) or ISCOM (immunostimulating complexes). Such adjuvants may protect the polypeptide from rapid dispersal by sequestering it in a local deposit, or they may contain substances that stimulate the host to secrete factors that are chemotactic for macrophages and other components of the immune system.
The nucleic acid molecule encoding the variable region of the light chain may be derived from the A30, A27 or 012 VK gene. In a preferred embodiment, the light chain is derived from the A30 VK gene. In an even more preferred embodiment, the nucleic acid molecule encoding the light chain contains no more than ten amino acid changes from the germline A30 VK gene, preferably no more than six amino acid changes, and even more preferably no more than three amino acid changes. In one embodiment, the antibody contains no greater than ten amino acid changes in either the VH or VL regions of the mutated anti-IGF-1 R antibody compared to the anti-IGF-1 R antibody prior to mutation. In a more preferred embodiment, there are no more than five amino acid changes in either the VH or VL regions of the mutated anti-IGF-1 R antibody, more preferably no more than three amino acid changes. In another embodiment, there are no more than fifteen amino acid changes in the constant domains, more preferably, no more than ten amino acid changes, even more preferably, no more than five amino acid changes.
SEQ ID NOS: 2, 6, 10, 14, 18 and 22 provide the amino acid sequences of the variable regions of six anti-IGF-1 R K light chains. SEQ ID NOS: 4, 8, 12, 16, 20 and 24 provide the amino acid sequences of the variable regions of six anti-IGF-1 R heavy chains. SEQ ID NO: 26 depicts the amino acid sequence and SEQ ID NO: 25 depicts the nucleic acid sequence encoding the constant region of the light chain of the anti-IGF-1 R antibodies 2.12.1 , 2.13.2, 2.14.3, 3.1.1 , 4.9.2, 4.17.3 and 6.1.1. SEQ ID NO: 28 depicts the amino acid sequence and SEQ ID NO: 27 depicts the nucleic acid sequence encoding the constant region of the heavy chain of the anti-IGF-1 R antibodies 2.12.1 , 2.13.2, 2.14.3, 3.1.1 , 4.9.2, 4.17.3 and 6.1.1. SEQ ID NOS: 30, 32, 34, 36 and 44 provide the amino acid sequences of the germline heavy chains DP-35, DP-47, DP-70, DP-71 and VIV-4, respectively. SEQ ID NO: 33 provides the nucleotide sequence of the germline heavy chain DP-70. SEQ ID NOS: 38, 40 and 42 provide the amino acid sequences of the three germline K light chains from which the six anti-IGF-1 R K light chains are derived. The anti-IGF-1 R antibodies can be incorporated into pharmaceutical compositions suitable for administration to a subject. Typically, the pharmaceutical composition comprises an antibody and a pharmaceutically acceptable carrier. As used herein, "pharmaceutically acceptable carrier" includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like that are physiologically compatible. Examples of pharmaceutically acceptable carriers include water, saline, phosphate buffered saline, dextrose, glycerol, ethanol and the like, as well as combinations thereof. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as mannitol, sorbitol, or sodium chloride in the
, composition. Minor amounts of auxiliary substances such as wetting or emulsifying agents, preservatives or buffers, which enhance the shelf life or effectiveness of the antibody or antibody portion, may also be included. The pharmaceutical compositions may be in a variety of forms. These include, for example, liquid, semi-solid and solid dosage forms, such as liquid solutions (e.g., injectable and infusible solutions), dispersions or suspensions, tablets, pills, powders, liposomes and suppositories. The preferred form depends on the intended mode of administration and therapeutic application. Typical preferred compositions are in the form of injectable or infusible solutions, such as compositions similar to those used for passive immunization of humans with other antibodies. A preferred mode of administration is parenteral (e.g., intravenous, subcutaneous, intraperitoneal, intramuscular, or infusion). In a preferred embodiment, the antibody is administered by intravenous infusion or injection. In another preferred embodiment, the antibody is administered by intramuscular or subcutaneous injection. As will be appreciated by the skilled artisan, the route and/or mode of administration will vary depending upon the desired results.
Therapeutic compositions typically must be sterile and stable under the conditions of manufacture and storage. The composition can be formulated as a solution, microemulsion, dispersion, liposome, or other ordered structure suitable to high drug concentration. Sterile injectable solutions can be prepared by incorporating the anti-IGF-1 R antibody in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle that contains a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and freeze-drying that yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof. The proper fluidity of a solution can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prolonged absorption of injectable compositions can be brought about by including in the composition an agent that delays absorption, for example, monostearate salts and gelatin. In certain embodiments, the active compound may be prepared with a carrier that will protect the compound against rapid release, such as a controlled release formulation, including implants, transdermal patches, and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Many methods for the preparation of such formulations are patented or generally known to those skilled in the art. See, e.g., Sustained and Controlled Release Drug Delivery Systems, J. R. Robinson, ed., Marcel Dekker, Inc., New York, 1978.
The pharmaceutical composition may include a "therapeutically effective amount" or a "prophylactically effective amount" of an antibody or antibody portion of the invention. A "therapeutically effective amount" refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired therapeutic result. A therapeutically effective amount of the antibody or antibody portion may vary according to factors such as the disease state, age, sex, and weight of the individual, and the ability of the antibody or antibody portion to elicit a desired response in the individual. A therapeutically effective amount is also one in which any toxic or detrimental effects of the antibody or antibody portion are outweighed by the therapeutically beneficial effects. A "prophylactically effective amount" refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired prophylactic result. Typically, since a prophylactic dose is used in subjects prior to or at an earlier stage of disease, the prophylactically effective amount will be less than the therapeutically effective amount.
Dosage regimens may be adjusted to provide the optimum desired response. For example, a single bolus may be administered, several divided doses may be administered over time or the dose may be proportionally reduced or increased as indicated by the exigencies of the therapeutic situation. Pharmaceutical composition comprising the antibody or comprising a combination therapy comprising the antibody and one or more additional therapeutic agents may be formulated for single or multiple doses. It is especially advantageous to formulate parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the mammalian subjects to be treated; each unit containing a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The specification for the dosage unit forms of the invention are dictated by and directly dependent on (a) the unique characteristics of the active compound and the particular therapeutic or prophylactic effect to be achieved, and (b) the limitations inherent in the art of compounding such an active compound for the treatment of sensitivity in individuals. A particularly useful formulation is 5 mg/ml anti-IGF-1 R antibody in a buffer of 2OmM sodium citrate, pH 5.5, 14OmM NaCI, and 0.2mg/ml polysorbate 80.
The antibody, with or without an additional agent, may be administered once, or more than once for at least the period of time until the condition is treated, palliated or cured. The antibody generally will be administered for as long as the tumor is present provided that the antibody causes the tumor or cancer to stop growing or to decrease in weight or volume. The antibody will generally be administered as part of a pharmaceutical composition as described supra. The dosage of antibody will generally be in the range of 0.025-100 mg/kg, more preferably 0.05-50 mg/kg, more preferably 0.05-20 mg/kg, and even more preferably 0.1-10 mg/kg. It is to be noted that dosage values may vary with the type and severity of the condition to be alleviated. It is to be further understood that for any particular subject, specific dosage regimens should be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the compositions, and that dosage ranges set forth herein are exemplary only and are not intended to limit the scope or practice of the claimed composition.
The antibody may be administered from three times daily to once every six months. The administration may be on a schedule such as three times daily, twice daily, once daily, once every two days, once every three days, once weekly, once every two weeks, once every month, once every two months, once every three months and once every six months. The antibody may be administered via an oral, mucosal, buccal, intranasal, inhalable, intravenous, subcutaneous, intramuscular, parenteral, intratumor or topical route.
The antibody may be administered at a site distant from the site of the tumor. The antibody may also be administered continuously via a minipump.
In certain embodiments, the antibody may be administered in an aerosol or inhalable form. Dry aerosol in the form of finely divided solid particles that are not dissolved or suspended in a liquid are also useful in the practice of the present invention. The pharmaceutical formulations of the present invention may be administered in the form of an aerosol spray using for example, a nebulizer such as those described in U.S. Patent Nos. 4,624,251 ; 3,703,173; 3,561 ,444; and 4,635,627. The serum concentration of the antibody may be measured by any method known in the art. The antibody may also be administered prophylactically in order to prevent a cancer or tumor from occurring. This may be especially useful in patients that have a "high normal" level of IGF-1 because these patients have been shown to have a higher risk of developing common cancers. See Rosen et al., supra. The antibody employed in the method of the invention can be labeled. This can be done by incorporation of a detectable marker, e.g., incorporation of a radiolabeled amino acid or attachment to a polypeptide of biotinyl moieties that can be detected by marked avidin (e.g., streptavidin containing a fluorescent marker or enzymatic activity that can be detected by optical or colorimetric methods). In certain situations, the label or marker can also be therapeutic. Various methods of labeling polypeptides and glycoproteins are known in the art and may be used. Examples of labels for polypeptides include, but are not limited to, the following: radioisotopes or radionuclides (e.g., 3H, 14C, 15N, 35S, 90Y, 99Tc, 111In, 125I, 131I), fluorescent labels (e.g., FITC, rhodamine, lanthanide phosphors), enzymatic labels (e.g., horseradish peroxidase, β-galactosidase, luciferase, alkaline phosphatase), chemiluminescent, biotinyl groups, predetermined polypeptide epitopes recognized by a secondary reporter (e.g., leucine zipper pair sequences, binding sites for secondary antibodies, metal binding domains, epitope tags). In some embodiments, labels are attached by spacer arms of various lengths to reduce potential steric hindrance.
The antibodies employed in the present invention are preferably derived from cells that express human immunoglobulin genes. Use of transgenic mice is known in the art to produce such "human" antibodies. One such method is described in U.S. Patent Application Serial No. 08/759,620, filed December 3, 1996. See also Mendez et al. Nature Genetics 15:146-156 (1997); Green and Jakobovits J. Exp. Med. 188:483-495 (1998); European Patent No. EP 0 463 151 (grant published June 12, 1996); and International Patent Application Nos. WO 94/02602, published February 3, 1994; WO 96/34096, published October 31 , 1996; and WO 98/24893, published June 11 , 1998. As noted above, the invention encompasses use of antibody fragments. Antibody fragments, such as Fv, F(ab')2 and Fab may be prepared by cleavage of the intact protein, e.g. by protease or chemical cleavage. Alternatively, a truncated gene is designed. For example, a chimeric gene encoding a portion of the F(ab')2 fragment would include DNA sequences encoding the CH1 domain and hinge region of the H chain, followed by a translational stop codon to yield the truncated molecule.
, In one approach, consensus sequences encoding the heavy and light chain J regions may be used to design oligonucleotides for use as primers to introduce useful restriction sites into the J region for subsequent linkage of V region segments to human C region segments. C region cDNA can be modified by site directed mutagenesis to place a restriction site at the analogous position in the human sequence.
Expression vectors for use in obtaining the antibodies employed in the invention include plasmids, retroviruses, cosmids, YACs, EBV derived episomes, and the like. A convenient vector is normally one that encodes a functionally complete human CH or CL immunoglobulin sequence, with appropriate restriction sites engineered so that any VH or VL sequence can be easily inserted and expressed. In such vectors, splicing usually occurs between the splice donor site in the inserted J region and the splice acceptor site preceding the human C region, and also at the splice regions that occur within the human CH exons. Polyadenylation and transcription termination occur at native chromosomal sites downstream of the coding regions. The resulting chimeric antibody may be joined to any strong promoter, including retroviral LTRs, e.g. SV-40 early promoter (Okayama et al. MoI. Cell. Bio. 3:280 (1983)), Rous sarcoma virus LTR (Gorman et al. Proc. Natl. Acad. Sci. 79:6777 (1982)), and moloney murine leukemia virus LTR (Grosschedl et al. Cell 41 :885 (1985)); native Ig promoters, etc.
Antibodies that are generated for use in the invention need not initially possess a particular desired isotype. Rather, the antibody as generated can possess any isotype and can be isotype switched thereafter using conventional techniques. These include direct recombinant techniques (see e.g., U.S. Patent No. 4,816,397), and cell-cell fusion techniques (see e.g., U.S. Patent No. 5,916,771 ).
As noted above, the effector function of the antibodies of the invention may be changed by isotype switching to an IgGI , lgG2, lgG3, lgG4, IgD, IgA, IgE, or IgM for various therapeutic uses. Furthermore, dependence on complement for cell killing can be avoided through the use of bispecifics, immunotoxins, or radiolabels, for example.
Bispecific antibodies can be generated that comprise (i) two antibodies: one with a specificity for IGF-1 R and the other for a second molecule (ii) a single antibody that has one chain specific for IGF-1 R and a second chain specific for a second molecule, or (iii) a single chain antibody that has specificity for IGF-1 R and the other molecule. Such bispecific antibodies can be generated using well known techniques, e.g., Fanger et al. Immunol. Methods 4:72-81 (1994); Wright and Harris, supra; and Traunecker et al. Int. J. Cancer (Suppl.) 7:51-52 (1992).
Antibodies for use in the invention also include "kappabodies" (III et al. Protein Eng. 10:949-57 (1997)), "minibodies" (Martin et al. EMBO J. 13:5303-9 (1994)), "diabodies" (Holliger et al. Proc. Natl. Acad. Sci. (USA) 90:6444-6448 (1993)), and "janusins" (Traunecker et al. EMSO J. 10:3655-3659 (1991) and Traunecker et al. Int. J. Cancer Suppl. 7:51-52 (1992)) may also be prepared.
The antibodies employed can be modified to act as immunotoxins by conventional techniques. See e.g., Vitetta Immunol. Today 14:252 (1993). See also U.S. Patent No. 5,194,594. Radiolabeled antibodies can also be prepared using well-known techniques. See e.g., Junghans et al. in Cancer Chemotherapy and Biotherapy 655-686 (2d edition, Chafner and Longo, eds., Lippincott Raven (1996)). See also U.S. Patent Nos. 4,681 ,581 , 4,735,210, 5,101 ,827, 5,102,990 (Re. 35,500), 5,648,471 , and 5,697,902.
Particular antibodies useful in practice of the invention include those described in International Patent Application No. WO 02/053596, which further describes antibodies 2.12.1, 2.13.2., 2.14.3, 3.1.1 , 4.9.2, and 4.17.3. As disclosed in that published application, hybridomas producing these antibodies were deposited in the American Type Culture Collection (ATCC), 10801 University Boulevard, Manassas, VA 20110-2209, on December 12, 2000 with the following deposit numbers:
Hybridoma Deposit No.
2.12.1 PTA-2792 2.13.2 PTA-2788
2.14.3 PTA-2790
3.1.1 PTA-2791
4.9.2 PTA-2789 4.17.3 PTA-2793 These antibodies are either fully human lgG2 or lgG4 heavy chains with human kappa light chains. In particular the invention concerns use of antibodies having amino acid sequences of these antibodies.
Antibodies employed in the invention preferably possess very high affinities, typically possessing Kds of from about 10~9 through about 10"11 M, when measured by either solid phase or solution phase.
Antibodies used in the present invention can be expressed in cell lines other than hybridoma cell lines. Sequences encoding the cDNAs or genomic clones for the particular antibodies can be used for transformation of suitable mammalian or nonmammalian host cells. Transformation can be by any known method for introducing polynucleotides into a host cell, including, for example packaging the polynucleotide in a virus (or into a viral vector) and transducing a host cell with the virus (or vector) or by transfection procedures known in the art, as exemplified by U.S. Patent Nos. 4,399,216, 4,912,040, 4,740,461 , and 4,959,455. Methods for introduction of heterologous polynucleotides into mammalian cells are well known in the art and include, but are not limited to, dextran-mediated transfection, calcium phosphate precipitation, polybrene mediated transfection, protoplast fusion, electroporation, particle bombardment, encapsulation of the polynucleotide(s) in liposomes, peptide conjugates, dendrimers, and direct microinjection of the DNA into nuclei.
Mammalian cell lines available as hosts for expression are well known in the art and include many immortalized cell lines available from the American Type Culture Collection (ATCC), including but not limited to Chinese hamster ovary (CHO) cells, NSO0, HeLa cells, baby hamster kidney (BHK) cells, monkey kidney cells (COS), and human hepatocellular carcinoma cells (e.g., Hep G2). Non-mammaiian cells can also be employed, including bacterial, yeast, insect, and plant cells. Site directed mutagenesis of the antibody CH2 domain to eliminate glycosylation may be preferred in order to prevent changes in either the immunogenicity, pharmacokinetic, and/or effector functions resulting from non-human glycosylation. The glutamine synthase system of expression is discussed in whole or part in connection with European Patent Nos. 0 216 846, 0 256 055, and 0 323 997, and European Patent Application No. 89303964.4.
Antibodies for use in the invention can also be produced transgenically through the generation of a mammal or plant that is transgenic for the immunoglobulin heavy and light chain sequences of interest and production of the antibody in a recoverable form therefrom. Transgenic antibodies can be produced in, and recovered from, the milk of goats, cows, or other mammals. See, e.g., U.S. Patent Nos. 5,827,690, 5,756,687, 5,750,172, and 5,741 ,957. '
The advantages of the present invention can be further appreciated by reference to the following examples. These examples serve intended to illustrate preferred embodiments of the invention and are by no means intended to limit the effective scope of the claims.
EXAMPLE I: Anti-IGF-1 R Antibodies in Combination with Docetaxel in the Treatment of Advanced
Non-Hematoloqic Malignancies \ Patients with advanced-stage non-hematologic malignancies (measurable disease defined by at least one lesion that can be accurately measured and whose size is >2 cm x 1 cm by conventional computed tomography (CT) scan or >1 cm x 1 cm by spiral CT scan) received a standard dose of docetaxel (TAXOTERE) (up to 75 mg/m2, using actual body weight to calculate body surface area (BSA)) by intravenous (IV) infusion over 1 hour on Day 1 only of each cycle. After the docetaxel infusion was completed, anti-IGF-1 R antibodies as described herein were administered intravenously in a 5 mg/ml liquid formulation at a dose between 0.1 mg/kg and 10 mg/kg. The treatment regimen was repeated after 21 days, with escalation of the anti-IGF-1 R antibody dose, and every 21 days thereafter until disease progression or unacceptable toxicity develops for a minimum of 2 cycles and a maximum of 17 cycles. The pre-medication regimen for docetaxel included oral dexamethasone 8 mg twice daily for three days starting one day prior to docetaxel administration. Prophylactic anti¬ emetics were provided as appropriate.
Dose escalation used an accelerated titration design utilizing a dose-doubling schema with 3-6 subjects per dose level (cohort). Within each new cohort there was no required waiting period between subjects. Subsequent cohorts were not opened until, the first subject at the current dose level had been observed for 21 days and subsequent subjects had been observed for 14 days.
The following endpoints were measured: safety, tolerability, pharmacokinetic (PK) parameters of the anti-IGF-1 R antibody; human anti-human antibody response (HAHA); response rate and time to progression; and number of circulating tumor cells (CTC) and circulating soluble IGF-1 R. EXAMPLE II: Anti-IGF-1 R Antibodies in Combination with Paclitaxel and Carboplatiπ in the
Treatment of Advanced Non-Small Cell Lung Cancer
In Part 1 of the study, patients with Stage INB or Stage IV or recurrent (after surgery/radiation), measurable, non-small cell lung cancer (NSCLC) who have received no prior chemotherapy received paclitaxel (TAXOL) at a standard dose of 200 mg/m2 by IV infusion over 3 hours. Prior to receiving paclitaxel, all patients received prophylactic anti¬ allergic/emetic medicines. Carboplatin (PARAPLATIN) was administered by IV infusion over 15-30 minutes; the dose was calculated based on the Calvert formula with a target area under the curve (AUC) of 6 mg/ml x min. After the carboplatin infusion was completed, anti-IGF-1 R antibodies as described herein were administered intravenously in a 5 mg/ml formulation at a dose between 0.05 mg/kg and 10 mg/kg. The treatment regimen was repeated after 21 days, with escalation of the anti-IGF-1 R antibody dose, and every 21 days thereafter until disease progression or unacceptable toxicity develops, for a minimum of 1 cycle and a maximum of 6 cycles.
Doses were escalated using an accelerated titration design utilizing a dose-doubling schema with 3-6 subjects per cohort. Within each new cohort there was no required waiting period between subjects. Subsequent cohorts were not opened until the first subject at the current dose level has been observed for 21 days and subsequent subjects have been observed for 14 days.
Once at least six patients have been observed for 21 days (i.e., completed one cycle), the randomized second portion of the study will begin.
Part 2 of the study is a two-arm randomized, non-comparative study of anti-IGF-1 R antibody in combination with paclitaxel and carboplatin (Arm A) and of paclitaxel and carboplatin alone (Arm B). On Day 1 of Part 2, the patients in both arms are given the same dosages of paclitaxel and carboplatin, over the same time periods, as in the first part. After administration of carboplatin, patients in Arm A are also given the same anti-IGF-1 R antibody dose they were given in Part 1. The dose is determined in view of the safety and tolerability demonstrated in Part 1. The treatment is repeated after 21 days, and every 21 days thereafter, until progression or unacceptable toxicity occurs for a minimum of 2 cycles and a maximum of 6.
The following endpoints are measured: PK parameters of the anti-IGF-1 R antibody, HAHA, response rate and time to progression, CTC, circulating IGF-1 , IGFBPs, and soluble circulating IGF-1 R. EXAMPLE
Anti-IGF-1 R in Combination with Docetaxel and Epirubicin in Metastatic Breast
Cancer
Patients having metastatic breast cancer with at least one lesion that can be accurately measured in two dimensions and whose size is >2 cm x 1 cm by conventional CT scan or >1 cm x 1 cm by spiral CT scan are given epirubicin 75 mg/m2 as a single 15 minute infusion. After a one hour pause, docetaxel (TAXOTERE) 75 mg/m2 is administered as a single IV infusion, followed by IV infusion of anti-IGF-1 R antibodies as described herein at a dose between 0.05 mg/kg and 10 mg/kg. Prophylactic anti-emetics are given as appropriate. The treatment is repeated after 21 days with escalation of the anti-IGF-1 R antibody dose, and every 21 days thereafter until disease progression or unacceptable toxicity develops for a minimum of 2 cycles and a maximum of 6.
Doses are escalated using an accelerated titration design utilizing a dose-doubling schema with 3-6 subjects per cohort. Within each new cohort there is no required waiting period between subjects. Subsequent cohorts may not be opened until the first subject at the current dose level has been observed for 21 days and subsequent subjects have been observed for 14 days.
The following endpoints are measured: PK parameters, HAHA, response rate and time to progression. Time to progression and overall survival are calculated using the Kaplan-Meier product limit method.
EXAMPLE IV: Anti-IGF-1 R in Combination with Docetaxel and Prednisone in
Hormone-Refractory Prostate Cancer
Subjects are patients with metastatic adenocarcinoma of the prostate who, after at least one hormonal treatment (orchiectomy, estrogens, LHRH therapy, etc.), have testosterone levels less than 50 ng/dL, prostate-specific antigen (PSA) above 20 ng/mL, and an increase in PSA > 50% over nadir value on hormonal therapy measured on 3 successive occasions at least 1 week apart. A pre-medication regimen for docetaxel includes oral dexamethasone 8 mg twice a day given for 3 days starting one day prior to docetaxel administration . A 75 mg/m2 dose of docetaxel (TAXOTERE) (using actual body weight to calculate BSA) is administered by IV infusion over 1 hour on Day 1 only of each cycle. After the docetaxel infusion is completed, anti-IGF-1 R antibodies as described herein are administered intravenously in a 5 mg/ml liquid formulation. Prednisone is given daily in two oral 5 mg doses per day, starting on Day 1. Prophylactic anti-emetics may be given as appropriate. The treatment regimen is repeated every 21 days (±3 days) until disease progression or unacceptable toxicity develops, for a maximum of 10 cycles.
The following endpoints are measured: PSA response, population PK parameters of the anti-IGF-1 R antibody, HAHA, total number of CTCs and CTCs expressing IGF-1 R. Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be readily apparent to those of ordinary skill in the art in light of the teachings of this invention that certain changes and modifications may be made thereto without departing from the spirit or scope of the appended claims.

Claims

1. A method for the treatment of a non-hematologic malignancy in a patient in need of such treatment comprising the step of administering to the patient a therapeutically effective amount of an antibody that specifically binds to IGF-1 R in combination with a therapeutically effective amount of at least one agent selected from the group consisting of an alkylating agent, a folate antagonist, a pyrimidine antagonist, a cytotoxic antibiotic, a platinum compound, a taxane, a vinca alkaloid, a topoisomerase inhibitor, an EGFR inhibitor, and a hormonal therapy agent.
2. , The method of claim 1 , wherein the agent is a taxane.
3. The method of claim 2, wherein the taxane is docetaxel.
4. The method of claim 2, wherein the taxane is paclitaxel.
5. The method of any one of claims 3 and 4, wherein the antibody and the taxane are administered in combination with an additional therapeutic agent selected from the group consisting of carboplatin, cisplatin, gemcitabine, capecitabine, epirubicin and prednisone.
6. The method of claim 5, wherein the additional therapeutic agent is carboplatin.
7. The method of claim 5, wherein the additional therapeutic agent is epirubicin.
8. The method of claim 5, wherein the additional therapeutic agent is prednisone.
9. The method of any one of claims 1-8, wherein the non-hematological malignancy is breast cancer.
10. The method of any one of claims 1-8, wherein the non-hematological malignancy is lung cancer.
11. The method of any one of claims 1-8, wherein the non-hematological malignancy is prostate cancer.
12. A pharmaceutical composition for the treatment of a non-hematologic malignancy according to the method of any one of claims 1-11 , comprising: a therapeutically effective amount of an antibody that specifically binds IGF-1 R, a therapeutically effective amount of at least one agent selected from the group consisting of an alkylating agent, a folate antagonist, a pyrimidine antagonist, a cytotoxic antibiotic, a platinum compound, a taxane, a vinca alkaloid, a topoisomerase inhibitor, an EGFR inhibitor, and a hormonal therapy agent; and a pharmaceutically acceptable carrier.
13. The composition of claim 12 wherein the antibody has the following properties: a binding affinity for human IGF-1 R of Kd of 8 x 10"9 or less; and inhibition of binding between human IGF-1 R and IGF-1 with an IC50 of less than 100 nM.
14. The composition of any one of claims 12 or 13 wherein the antibody comprises at least one of the group consisting of: (a) a heavy chain comprising the amino acid sequences of CDR-1 , CDR-2, and CDR-
3 of an antibody selected from the group consisting of 2.12.1 , 2.13.2, 2.14.3, 4.9.2, 4.17.3, f and 6.1.1 ;
(b) a light chain comprising the amino acid sequences of CDR-1 , CDR-2, and CDR-3 of an antibody selected from the group consisting of 2.12.1 , 2.13.2, 2.14.3, 4.9.2, 4.17.3, and 6.1.1 ; and
(c) sequences having changes from the CDR sequences of an antibody selected from the group consisting of 2.12.1 , 2.13.2, 2.14.3, 4.9.2, 4.17.3, and 6.1.1 , said sequences being selected from the group consisting of conservative changes, wherein the conservative changes are selected from the group consisting of replacement of nonpolar residues by other nonpolar residues, replacement of polar charged residues by other polar uncharged residues, replacement of polar charged residues by other polar charged residues, and substitution of structurally similar residues; and non-conservative substitutions, wherein the non- conservative substitutions are selected from the group consisting of substitution of polar charged residue for polar uncharged residues and substitution of nonpolar residues for polar residues, additions and deletions.
15. The composition of any one of claims 12-14, wherein the antibody comprises a heavy chain comprising the amino acid sequences of CDR-1 , CDR-2, and CDR-3, and a light chain comprising the amino acid sequences of CDR-1, CDR-2, and CDR-3, of an antibody selected from the group consisting of 2.12.1 , 2.13.2, 2.14.3, 4.9.2, 4.17.3, and 6.1.1.
16. The composition of any one of claims 12-15, wherein the antibody is selected from the group consisting of an antibody comprising a heavy chain amino acid sequence derived from human gene DP-47 and a light chain amino acid sequence derived from human gene A30.
PCT/IB2005/002096 2004-07-16 2005-07-04 Combination treatment for non-hematologic malignancies using an anti-igf-1r antibody WO2006008639A1 (en)

Priority Applications (15)

Application Number Priority Date Filing Date Title
MX2007000610A MX2007000610A (en) 2004-07-16 2005-07-04 Combination treatment for non-hematologic malignancies using an anti-ogf-1r antibody.
CA002573821A CA2573821A1 (en) 2004-07-16 2005-07-04 Combination treatment for non-hematologic malignancies using an anti-igf-1r antibody
AU2005264063A AU2005264063B2 (en) 2004-07-16 2005-07-04 Combination treatment for non-hematologic malignancies using an anti-igf-1r antibody
JP2007520919A JP2008506681A (en) 2004-07-16 2005-07-04 Combination therapy for non-blood malignant tumors using anti-IGF-1R antibody
EP05757374A EP1802341A1 (en) 2004-07-16 2005-07-04 Combination treatment for non-hematologic malignancies using an anti-igf-1r antibody
BRPI0513200-2A BRPI0513200A (en) 2004-07-16 2005-07-04 use of an anti-igf-1r antibody in the preparation of a medicament for combined treatment for nonhematological malignancies
CN2005800240273A CN101014365B (en) 2004-07-16 2005-07-04 Combination treatment for non-hematologic malignancies using an anti-igf-1r antibody
NZ552091A NZ552091A (en) 2004-07-16 2005-07-04 Combination treatment for non-hematologic malignancies using an anti-IGF-1R antibody
IL180422A IL180422A0 (en) 2004-07-16 2006-12-28 Combination treatment for non - hematologic malignancies using an anti-ogf-1r antibody
NO20070702A NO20070702L (en) 2004-07-16 2007-02-07 Combination therapy for non-hematologic malignancy using anti-OGF-1R antibody
HK07110312.3A HK1105151A1 (en) 2004-07-16 2007-09-21 Combination treatment for non-hematologic malignancies using an anti-igf-1r antibody
AU2009210360A AU2009210360B2 (en) 2004-07-16 2009-08-17 Combination treatment for non-hematologic malignancies using an anti-IGF-1R antibody
IL210401A IL210401A0 (en) 2004-07-16 2010-12-30 Combination treatment for non - hematologic malignancies using an anti-ogf-1r antibody
IL210400A IL210400A0 (en) 2004-07-16 2010-12-30 Combination treatment for non - hematologic malignancies using an anti-ogf-1r antibody
IL210399A IL210399A0 (en) 2004-07-16 2010-12-30 Combination treatment for non - hematologic malignancies using an anti-ogf-1r antibody

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58872104P 2004-07-16 2004-07-16
US60/588,721 2004-07-16

Publications (2)

Publication Number Publication Date
WO2006008639A1 true WO2006008639A1 (en) 2006-01-26
WO2006008639A8 WO2006008639A8 (en) 2007-02-15

Family

ID=35058695

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2005/002096 WO2006008639A1 (en) 2004-07-16 2005-07-04 Combination treatment for non-hematologic malignancies using an anti-igf-1r antibody

Country Status (17)

Country Link
US (2) US7618626B2 (en)
EP (4) EP2335727A3 (en)
JP (1) JP2008506681A (en)
KR (2) KR20080019733A (en)
CN (1) CN101014365B (en)
AR (1) AR049985A1 (en)
AU (2) AU2005264063B2 (en)
BR (1) BRPI0513200A (en)
CA (1) CA2573821A1 (en)
HK (1) HK1105151A1 (en)
IL (4) IL180422A0 (en)
MX (1) MX2007000610A (en)
NO (1) NO20070702L (en)
NZ (1) NZ552091A (en)
RU (1) RU2342159C2 (en)
TW (2) TW200812621A (en)
WO (1) WO2006008639A1 (en)

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007141626A1 (en) * 2006-06-02 2007-12-13 Pfizer Products Inc. Circulating tumor cell assay
WO2008098917A2 (en) * 2007-02-14 2008-08-21 Glaxo Group Limited Novel antibodies against igf-ir
WO2008108986A2 (en) * 2007-03-02 2008-09-12 Amgen Inc. Methods and compositions for treating tumor diseases
WO2008144720A2 (en) * 2007-05-21 2008-11-27 University Of Washington Inhibitors of igf-1r signaling for the treatment of respiratory disorders
WO2009080278A1 (en) 2007-12-21 2009-07-02 F. Hoffmann-La Roche Ag Stability testing of antibodies
JP2009536931A (en) * 2006-05-12 2009-10-22 トビアス タイヒマン アレクサンダー Novel use of 4,17β-dihydroxyandrost-4-en-3-one
US7638605B2 (en) 2003-05-01 2009-12-29 ImClone, LLC Fully human antibodies directed against the human insulin-like growth factor-1 receptor
EP2236139A1 (en) 2009-03-31 2010-10-06 F. Hoffmann-La Roche AG Combination therapy of erlotinib with an anti-IGF-1R antibody, which does not inhibit binding of insulin to the insulin receptor
US7846724B2 (en) 2006-04-11 2010-12-07 Hoffmann-La Roche Inc. Method for selecting CHO cell for production of glycosylated antibodies
US7972600B2 (en) 2006-02-03 2011-07-05 Imclone Llc IGF-IR antagonists as adjuvants for treatment of prostate cancer
WO2011101328A2 (en) 2010-02-18 2011-08-25 Roche Glycart Ag Treatment with a humanized igg class anti egfr antibody and an antibody against insulin like growth factor 1 receptor
WO2011161119A1 (en) 2010-06-22 2011-12-29 F. Hoffmann-La Roche Ag Antibodies against insulin-like growth factor i receptor and uses thereof
US8128929B2 (en) 2005-06-17 2012-03-06 Imclone Llc Antibodies against PDGFRa
US8318159B2 (en) 2008-12-12 2012-11-27 Boehringer Ingelheim International Gmbh Anti-IGF antibodies
EP2631653A1 (en) 2012-02-24 2013-08-28 Charité - Universitätsmedizin Berlin Identification of modulators of binding properties of antibodies reactive with a member of the insulin receptor family
US8580254B2 (en) 2007-06-19 2013-11-12 Boehringer Ingelheim International Gmbh Anti-IGF antibodies
AU2012203443B2 (en) * 2007-03-02 2014-03-06 Amgen Inc. Methods and compositions for treating tumor diseases
EP2727941A1 (en) 2012-11-05 2014-05-07 MAB Discovery GmbH Method for the production of multispecific antibodies
WO2014067642A1 (en) 2012-11-05 2014-05-08 Mab Discovery Gmbh Method for the production of multispecific antibodies
WO2014135611A1 (en) * 2013-03-07 2014-09-12 Boehringer Ingelheim International Gmbh Combination therapy for neoplasia treatment
US10751422B2 (en) 2015-03-09 2020-08-25 Agensys, Inc. Antibody drug conjugates (ADC) that bind to FLT3 proteins
US11021728B2 (en) 2009-10-26 2021-06-01 Hoffmann-La Roche Inc. Method for the production of a glycosylated immunoglobulin

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2484000A1 (en) * 2002-05-24 2003-12-04 Schering Corporation Neutralizing human anti-igfr antibody
US7310537B2 (en) * 2003-04-25 2007-12-18 Nokia Corporation Communication on multiple beams between stations
JP2007510434A (en) 2003-11-12 2007-04-26 シェーリング　コーポレイション A plasmid system for multigene expression.
PE20050928A1 (en) * 2003-11-21 2005-11-08 Schering Corp THERAPEUTIC COMBINATIONS OF ANTI-IGFR1 ANTIBODY
MX2007006640A (en) * 2004-12-03 2007-06-19 Schering Corp Biomarkers for pre-selection of patients for anti-igf1r therapy.
EP1879587A2 (en) * 2005-04-15 2008-01-23 Schering Corporation Methods and compositions for treating or preventing cancer
US20060286103A1 (en) * 2005-06-15 2006-12-21 Parag Kolhe Stable antibody formulation
DK1926996T3 (en) 2005-09-20 2012-01-23 Osi Pharmaceuticals Llc Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
US7745400B2 (en) * 2005-10-14 2010-06-29 Gregg Feinerman Prevention and treatment of ocular side effects with a cyclosporin
US9839667B2 (en) 2005-10-14 2017-12-12 Allergan, Inc. Prevention and treatment of ocular side effects with a cyclosporin
JP5335432B2 (en) 2005-11-17 2013-11-06 オーエスアイ・フアーマシユーテイカルズ・エル・エル・シー Fused bicyclic mTOR inhibitor
EP2338488A1 (en) * 2006-05-26 2011-06-29 Bayer HealthCare, LLC Drug combinations with substituted diaryl ureas for the treatment of cancer
WO2008079849A2 (en) * 2006-12-22 2008-07-03 Genentech, Inc. Antibodies to insulin-like growth factor receptor
JP2010532758A (en) * 2007-07-06 2010-10-14 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド Combination anticancer therapy
WO2009008992A2 (en) * 2007-07-06 2009-01-15 Osi Pharmaceuticals Inc. Combination anti-cancer therapy comprising an inhibitor of both mtorc1 and mt0rc2
WO2009045389A2 (en) * 2007-10-03 2009-04-09 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
JP2010540960A (en) * 2007-10-03 2010-12-24 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド Biological marker predicting anticancer response to insulin-like growth factor-1 receptor kinase inhibitor
JP2011118449A (en) 2008-03-26 2011-06-16 Japan Breast Cancer Research Group Administration method proposal device
KR20180117734A (en) 2008-11-22 2018-10-29 제넨테크, 인크. Use of anti-vegf antibody in combination with chemotherapy for treating breast cancer
WO2010099137A2 (en) * 2009-02-26 2010-09-02 Osi Pharmaceuticals, Inc. In situ methods for monitoring the emt status of tumor cells in vivo
WO2010146059A2 (en) 2009-06-16 2010-12-23 F. Hoffmann-La Roche Ag Biomarkers for igf-1r inhibitor therapy
WO2011008768A1 (en) * 2009-07-13 2011-01-20 Wayne State University Modified egfr ectodomain
WO2011072240A1 (en) 2009-12-10 2011-06-16 Cedars-Sinai Medical Center Drug delivery of temozolomide for systemic based treatment of cancer
WO2011109584A2 (en) * 2010-03-03 2011-09-09 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
US9623041B2 (en) 2010-12-30 2017-04-18 Cedars-Sinai Medical Center Polymalic acid-based nanobiopolymer compositions
WO2012091718A1 (en) * 2010-12-30 2012-07-05 Cedars-Sinai Medical Center Polymalic acid-based nanobiopolymer compositions and methods for treating cancer
EP2702173A1 (en) 2011-04-25 2014-03-05 OSI Pharmaceuticals, LLC Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
WO2013060872A1 (en) * 2011-10-27 2013-05-02 Boehringer Ingelheim International Gmbh Anticancer combination therapy
CN103319598B (en) * 2013-05-13 2014-10-22 杭州德同生物技术有限公司 Insulin-like growth factor-1 receptor (IGF-1R) resistant antibody and coding genes and applications thereof
US9923862B2 (en) * 2015-06-23 2018-03-20 International Business Machines Corporation Communication message consolidation with content difference formatting
WO2021025554A1 (en) 2019-08-02 2021-02-11 Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Combination comprising an activator of the glucocorticoid receptor and an inhibitor of ifg-1 signaling for carcinoma treatment
CN113512116B (en) 2020-04-10 2022-09-20 苏州普乐康医药科技有限公司 anti-IGF-1R antibody and application thereof
CN118059229A (en) * 2020-10-14 2024-05-24 维里迪安治疗公司 Compositions and methods for treating thyroid eye disorders
IL302068A (en) 2020-10-14 2023-06-01 Viridian Therapeutics Inc Compositions and methods for treatment of thyroid eye disease
WO2024047130A1 (en) 2022-08-31 2024-03-07 Relaxera Pharmazeutische Gesellschaft mbH & Co. KG Immunosuppressive medicament and method of treatment

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030165502A1 (en) * 2000-06-13 2003-09-04 City Of Hope Single-chain antibodies against human insulin-like growth factor I receptor: expression, purification, and effect on tumor growth
US20030235582A1 (en) * 2002-06-14 2003-12-25 Immunogen, Inc. Anti-IGF-I receptor antibody
US20040086503A1 (en) * 2001-01-05 2004-05-06 Cohen Bruce D. Antibodies to insulin-like growth factor I receptor
WO2005016970A2 (en) * 2003-05-01 2005-02-24 Imclone Systems Incorporated Fully human antibodies directed against the human insulin-like growth factor-1 receptor
WO2005016967A2 (en) * 2003-08-13 2005-02-24 Pfizer Products Inc. Modified human igf-1r antibodies

Family Cites Families (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US577085A (en) * 1897-02-16 Bicycle-saddle carriage
US3561444A (en) 1968-05-22 1971-02-09 Bio Logics Inc Ultrasonic drug nebulizer
US3703173A (en) 1970-12-31 1972-11-21 Ted A Dixon Nebulizer and tent assembly
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4681581A (en) 1983-12-05 1987-07-21 Coates Fredrica V Adjustable size diaper and folding method therefor
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US6054561A (en) 1984-02-08 2000-04-25 Chiron Corporation Antigen-binding sites of antibody molecules specific for cancer antigens
US4624251A (en) 1984-09-13 1986-11-25 Riker Laboratories, Inc. Apparatus for administering a nebulized substance
US4635627A (en) 1984-09-13 1987-01-13 Riker Laboratories, Inc. Apparatus and method
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
JP2532858B2 (en) 1985-04-01 1996-09-11 セルテツク リミテツド Transformed myeloma cell line
US4735210A (en) 1985-07-05 1988-04-05 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5101827A (en) 1985-07-05 1992-04-07 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5776093A (en) 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
US5750172A (en) 1987-06-23 1998-05-12 Pharming B.V. Transgenic non human mammal milk
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5648471A (en) 1987-12-03 1997-07-15 Centocor, Inc. One vial method for labeling antibodies with Technetium-99m
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
GB8827305D0 (en) 1988-11-23 1988-12-29 British Bio Technology Compounds
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US4968516A (en) 1989-07-24 1990-11-06 Thompson Neal W Method and apparatus for cooking foodstuffs using auxiliary steam
US5102990A (en) 1989-08-09 1992-04-07 Rhomed Incorporated Direct radiolabeling of antibodies and other proteins with technetium or rhenium
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
WO1991010741A1 (en) 1990-01-12 1991-07-25 Cell Genesys, Inc. Generation of xenogeneic antibodies
US6657103B1 (en) 1990-01-12 2003-12-02 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5151510A (en) 1990-04-20 1992-09-29 Applied Biosystems, Inc. Method of synethesizing sulfurized oligonucleotide analogs
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
AU665190B2 (en) 1990-07-10 1995-12-21 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5165424A (en) 1990-08-09 1992-11-24 Silverman Harvey N Method and system for whitening teeth
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5612205A (en) 1990-08-29 1997-03-18 Genpharm International, Incorporated Homologous recombination in mammalian cells
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5194594A (en) 1990-09-07 1993-03-16 Techniclone, Inc. Modified antibodies
DE69129154T2 (en) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. METHOD FOR ENRICHING PROTEIN VARIANTS WITH CHANGED BINDING PROPERTIES
ATE439435T1 (en) 1991-03-01 2009-08-15 Dyax Corp CHIMERIC PROTEIN COMPRISING MICROPROTEIN HAVING TWO OR MORE DISULFIDE BONDS AND FORMATIONS THEREOF
DE69233367T2 (en) 1991-04-10 2005-05-25 The Scripps Research Institute, La Jolla LIBRARIES OF HETERODIMERIC RECEPTORS BY PHAGEMIDES
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
DE4122599C2 (en) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid for screening antibodies
AU2515992A (en) 1991-08-20 1993-03-16 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
ATE181571T1 (en) 1991-09-23 1999-07-15 Medical Res Council METHODS FOR PRODUCING HUMANIZED ANTIBODIES
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
JPH05244982A (en) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd Humanized b-b10
US5777085A (en) 1991-12-20 1998-07-07 Protein Design Labs, Inc. Humanized antibodies reactive with GPIIB/IIIA
DE69334351D1 (en) 1992-02-06 2011-05-12 Novartis Vaccines & Diagnostic Biosynthetic binding protein for tumor markers
EP0592677B1 (en) 1992-02-18 2001-11-07 Otsuka Kagaku Kabushiki Kaisha Beta-LACTAM COMPOUND AND CEPHEM COMPOUND, AND PRODUCTION THEREOF
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
ES2301158T3 (en) 1992-07-24 2008-06-16 Amgen Fremont Inc. XENOGENIC ANTIBODY PRODUCTION.
US6177401B1 (en) 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
US5455258A (en) 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
AU693436B2 (en) 1993-03-09 1998-07-02 Genzyme Corporation Isolation of components of interest from milk
US5625825A (en) 1993-10-21 1997-04-29 Lsi Logic Corporation Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
US5643763A (en) 1994-11-04 1997-07-01 Genpharm International, Inc. Method for making recombinant yeast artificial chromosomes by minimizing diploid doubling during mating
US5863949A (en) 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
US6091001A (en) 1995-03-29 2000-07-18 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
WO1996033172A1 (en) 1995-04-20 1996-10-24 Pfizer Inc. Arylsulfonyl hydroxamic acid derivatives as mmp and tnf inhibitors
AU705616B2 (en) 1995-04-21 1999-05-27 Cell Genesys, Inc. Generation of large genomic DNA deletions
CA2761116A1 (en) 1995-04-27 1996-10-31 Amgen Fremont Inc. Human antibodies derived from immunized xenomice
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
GB9520822D0 (en) 1995-10-11 1995-12-13 Wellcome Found Therapeutically active compounds
JP2000500654A (en) 1995-11-14 2000-01-25 トーマス・ジェファーソン・ユニバーシティ Induced resistance to tumor growth by soluble IGF-1 receptor
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
ATE225343T1 (en) 1995-12-20 2002-10-15 Hoffmann La Roche MATRIX METALLOPROTEASE INHIBITORS
DK0885198T3 (en) 1996-03-05 2002-03-25 Astrazeneca Ab 4-anilinoquinazoline derivatives
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
US5994619A (en) 1996-04-01 1999-11-30 University Of Massachusetts, A Public Institution Of Higher Education Of The Commonwealth Of Massachusetts, As Represented By Its Amherst Campus Production of chimeric bovine or porcine animals using cultured inner cell mass cells
IL118626A0 (en) 1996-06-11 1996-10-16 Xtl Biopharmaceuticals Limited Anti HBV antibody
EP0818442A3 (en) 1996-07-12 1998-12-30 Pfizer Inc. Cyclic sulphone derivatives as inhibitors of metalloproteinases and of the production of tumour necrosis factor
AR007857A1 (en) 1996-07-13 1999-11-24 Glaxo Group Ltd HETERO-CYCLIC COMPOUNDS FUSED AS PROTEIN INHIBITORS, THYROSINE KINASE, THEIR PREPARATION METHODS, INTERMEDIARY USE IN MEDICINE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
DE69718472T2 (en) 1996-07-13 2003-11-06 Glaxo Group Ltd., Greenford BICYCLIC HETEROAROMATIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS
HRP970371A2 (en) 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
PT1500329E (en) 1996-12-03 2012-06-18 Amgen Fremont Inc Human antibodies that specifically bind human tnf alpha
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
GB9801690D0 (en) 1998-01-27 1998-03-25 Pfizer Ltd Therapeutic agents
AU2978899A (en) 1998-03-03 1999-09-20 Abgenix, Inc. Cd147 binding molecules as therapeutics
US20020029391A1 (en) 1998-04-15 2002-03-07 Claude Geoffrey Davis Epitope-driven human antibody production and gene expression profiling
US20020142374A1 (en) 1998-08-17 2002-10-03 Michael Gallo Generation of modified molecules with increased serum half-lives
ES2213985T3 (en) 1998-11-05 2004-09-01 Pfizer Products Inc. 5-OXO-PIRROLIDIN-2-CARBOXYLIC ACID HYDROXYAMIDE DERIVATIVES.
ES2340745T3 (en) 1998-12-23 2010-06-08 Pfizer Inc. HUMAN MONOCLONAL ANTIBODIES AGAINST CTLA-4.
PL355170A1 (en) * 1999-11-10 2004-04-05 Warner-Lambert Company Combination chemotherapy
US6593308B2 (en) * 1999-12-03 2003-07-15 The Regents Of The University Of California Targeted drug delivery with a hyaluronan ligand
CA2409652A1 (en) * 2000-05-15 2001-11-22 Giorgio Massimini Aromatase inhibitors and monoclonal anti-her2 antibodies as antitumors agents
DK1292591T3 (en) 2000-06-22 2005-05-30 Pfizer Prod Inc Bicyclic derivatives for the treatment of abnormal cell growth
CA2484000A1 (en) 2002-05-24 2003-12-04 Schering Corporation Neutralizing human anti-igfr antibody
JP4305808B2 (en) * 2002-07-03 2009-07-29 太陽誘電株式会社 Multilayer capacitor
CA2518980A1 (en) 2003-03-14 2004-09-30 Pharmacia Corporation Antibodies to igf-i receptor for the treatment of cancers
CA2519113C (en) 2003-04-02 2012-06-05 F. Hoffmann-La Roche Ag Antibodies against insulin-like growth factor i receptor and uses thereof
AR046071A1 (en) 2003-07-10 2005-11-23 Hoffmann La Roche ANTIBODIES AGAINST RECEIVER I OF THE INSULINAL TYPE GROWTH FACTOR AND THE USES OF THE SAME

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030165502A1 (en) * 2000-06-13 2003-09-04 City Of Hope Single-chain antibodies against human insulin-like growth factor I receptor: expression, purification, and effect on tumor growth
US20040086503A1 (en) * 2001-01-05 2004-05-06 Cohen Bruce D. Antibodies to insulin-like growth factor I receptor
US20030235582A1 (en) * 2002-06-14 2003-12-25 Immunogen, Inc. Anti-IGF-I receptor antibody
WO2005016970A2 (en) * 2003-05-01 2005-02-24 Imclone Systems Incorporated Fully human antibodies directed against the human insulin-like growth factor-1 receptor
WO2005016967A2 (en) * 2003-08-13 2005-02-24 Pfizer Products Inc. Modified human igf-1r antibodies

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BENINI S ET AL: "INHIBITION OF INSULIN-LIKE GROWTH FACTOR I RECEPTOR INCREASES THE ANTITUMOR ACTIVITY OF DOXORUBICIN AND VINCRISTINE AGAINST EWING'S SARCOMA CELLS", CLINICAL CANCER RESEARCH, THE ASSOCIATION, DENVILLE, NJ, US, vol. 7, no. 6, June 2001 (2001-06-01), pages 1790 - 1797, XP001187566, ISSN: 1078-0432 *
LU D ET AL: "Simultaneous blockade of both the epidermal growth factor receptor and the insulin-like growth factor receptor signaling pathways in cancer cells with a fully human recombinant bispecific antibody", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM,, US, vol. 279, no. 4, 23 January 2004 (2004-01-23), pages 2856 - 2865, XP002316541, ISSN: 0021-9258 *
MALONEY E K ET AL: "An anti-insulin-like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 63, no. 16, 15 August 2003 (2003-08-15), pages 5073 - 5083, XP002978956, ISSN: 0008-5472 *
See also references of EP1802341A1 *
YE J-J ET AL: "COMBINED EFFECTS OF TAMOXIFEN AND A CHIMERIC HUMANIZED SINGLE CHAIN ANTIBODY AGAINST THE TYPE I IGF RECEPTOR ON BREAST TUMOR GROWTH IN VIVO", HORMONE AND METABOLIC RESEARCH, THIEME-STRATTON, STUTTGART, DE, vol. 35, no. 11/12, November 2003 (2003-11-01), pages 836 - 842, XP009055889, ISSN: 0018-5043 *

Cited By (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7638605B2 (en) 2003-05-01 2009-12-29 ImClone, LLC Fully human antibodies directed against the human insulin-like growth factor-1 receptor
US7968093B2 (en) 2003-05-01 2011-06-28 Imclone Llc Fully human antibodies directed against the human insulin-like growth factor-1 receptor
US8574578B2 (en) 2005-06-17 2013-11-05 Imclone Llc Antibodies against PDGFRα to inhibit tumor growth
US8425911B2 (en) 2005-06-17 2013-04-23 Imclone Llc Methods of treating secondary bone tumors with antibodies against PDGFR alpha
US8128929B2 (en) 2005-06-17 2012-03-06 Imclone Llc Antibodies against PDGFRa
US7972600B2 (en) 2006-02-03 2011-07-05 Imclone Llc IGF-IR antagonists as adjuvants for treatment of prostate cancer
US11673958B2 (en) 2006-04-11 2023-06-13 Hoffmann-La Roche Inc. Glycosylated antibodies
US7846724B2 (en) 2006-04-11 2010-12-07 Hoffmann-La Roche Inc. Method for selecting CHO cell for production of glycosylated antibodies
US8703919B2 (en) 2006-04-11 2014-04-22 Hoffmann-La Roche Inc. Glycosylated antibodies
US9138477B2 (en) 2006-05-12 2015-09-22 Mabel Gmbh Uses for 4,17β-dihydroxyandrost-4-ene-3-one
JP2009536932A (en) * 2006-05-12 2009-10-22 トビアス タイヒマン アレクサンダー Drugs for breast cancer and related diseases
JP2009536931A (en) * 2006-05-12 2009-10-22 トビアス タイヒマン アレクサンダー Novel use of 4,17β-dihydroxyandrost-4-en-3-one
US9114163B2 (en) 2006-05-12 2015-08-25 Mabel Gmbh Medication against breast cancer and related diseases
US9610292B2 (en) 2006-05-12 2017-04-04 Mabel Gmbh Uses for 4,17β-dihydroxyandrost-4-ene-3-one
US8940493B2 (en) 2006-06-02 2015-01-27 Veridex Llc Circulating tumor cell assay
RU2429486C2 (en) * 2006-06-02 2011-09-20 Пфайзер Продактс Инк. Circulating tumour cell assay
AU2007255110B8 (en) * 2006-06-02 2014-04-10 Pfizer Products Inc. Circulating tumor cell assay
CN101600966B (en) * 2006-06-02 2014-07-02 辉瑞产品公司 Circulating tumor cell assay
AU2007255110A8 (en) * 2006-06-02 2014-04-10 Pfizer Products Inc. Circulating tumor cell assay
AU2007255110B2 (en) * 2006-06-02 2014-03-20 Pfizer Products Inc. Circulating tumor cell assay
WO2007141626A1 (en) * 2006-06-02 2007-12-13 Pfizer Products Inc. Circulating tumor cell assay
WO2008098917A2 (en) * 2007-02-14 2008-08-21 Glaxo Group Limited Novel antibodies against igf-ir
WO2008098917A3 (en) * 2007-02-14 2008-10-09 Glaxo Group Ltd Novel antibodies against igf-ir
AU2008223541B2 (en) * 2007-03-02 2012-04-05 Amgen Inc. Methods and compositions for treating tumor diseases
WO2008108986A3 (en) * 2007-03-02 2009-02-05 Amgen Inc Methods and compositions for treating tumor diseases
AU2012203443B2 (en) * 2007-03-02 2014-03-06 Amgen Inc. Methods and compositions for treating tumor diseases
WO2008108986A2 (en) * 2007-03-02 2008-09-12 Amgen Inc. Methods and compositions for treating tumor diseases
US8178091B2 (en) 2007-05-21 2012-05-15 University Of Washington Compositions and methods for the treatment of respiratory disorders
WO2008144720A2 (en) * 2007-05-21 2008-11-27 University Of Washington Inhibitors of igf-1r signaling for the treatment of respiratory disorders
WO2008144720A3 (en) * 2007-05-21 2009-01-08 Univ Washington Inhibitors of igf-1r signaling for the treatment of respiratory disorders
US8580254B2 (en) 2007-06-19 2013-11-12 Boehringer Ingelheim International Gmbh Anti-IGF antibodies
WO2009080278A1 (en) 2007-12-21 2009-07-02 F. Hoffmann-La Roche Ag Stability testing of antibodies
US8318159B2 (en) 2008-12-12 2012-11-27 Boehringer Ingelheim International Gmbh Anti-IGF antibodies
US11299538B2 (en) 2008-12-12 2022-04-12 Boehringer Ingelheim International Gmbh Anti-IGF antibodies
US10179810B2 (en) 2008-12-12 2019-01-15 Boehringer Ingelheim International Gmbh Anti-IGF antibodies
EP2236139A1 (en) 2009-03-31 2010-10-06 F. Hoffmann-La Roche AG Combination therapy of erlotinib with an anti-IGF-1R antibody, which does not inhibit binding of insulin to the insulin receptor
US11377678B2 (en) 2009-10-26 2022-07-05 Hoffman-La Roche Inc. Method for the production of a glycosylated immunoglobulin
US11136610B2 (en) 2009-10-26 2021-10-05 Hoffmann-La Roche Inc. Method for the production of a glycosylated immunoglobulin
US11021728B2 (en) 2009-10-26 2021-06-01 Hoffmann-La Roche Inc. Method for the production of a glycosylated immunoglobulin
WO2011101328A2 (en) 2010-02-18 2011-08-25 Roche Glycart Ag Treatment with a humanized igg class anti egfr antibody and an antibody against insulin like growth factor 1 receptor
WO2011161119A1 (en) 2010-06-22 2011-12-29 F. Hoffmann-La Roche Ag Antibodies against insulin-like growth factor i receptor and uses thereof
WO2013124482A2 (en) 2012-02-24 2013-08-29 Charité - Universitätsmedizin Berlin Identification of modulators of binding properties of antibodies reactive with a member of the insulin receptor family
EP3527988A2 (en) 2012-02-24 2019-08-21 BerYsol GmbH Identification of antibodies reactive with a member of the insulin receptor family
EP2631653A1 (en) 2012-02-24 2013-08-28 Charité - Universitätsmedizin Berlin Identification of modulators of binding properties of antibodies reactive with a member of the insulin receptor family
WO2014067642A1 (en) 2012-11-05 2014-05-08 Mab Discovery Gmbh Method for the production of multispecific antibodies
EP2727941A1 (en) 2012-11-05 2014-05-07 MAB Discovery GmbH Method for the production of multispecific antibodies
JP2016511265A (en) * 2013-03-07 2016-04-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Combination therapy for the treatment of neoplasms
EA034884B1 (en) * 2013-03-07 2020-04-01 Бёрингер Ингельхайм Интернациональ Гмбх Combination therapy for treatment of prostate cancer
CN105007942A (en) * 2013-03-07 2015-10-28 勃林格殷格翰国际有限公司 Combination therapy for neoplasia treatment
WO2014135611A1 (en) * 2013-03-07 2014-09-12 Boehringer Ingelheim International Gmbh Combination therapy for neoplasia treatment
US10751422B2 (en) 2015-03-09 2020-08-25 Agensys, Inc. Antibody drug conjugates (ADC) that bind to FLT3 proteins

Also Published As

Publication number Publication date
RU2342159C2 (en) 2008-12-27
EP1802341A1 (en) 2007-07-04
KR20070036130A (en) 2007-04-02
HK1105151A1 (en) 2008-02-01
CN101014365A (en) 2007-08-08
AU2009210360B2 (en) 2011-09-22
TW200612987A (en) 2006-05-01
WO2006008639A8 (en) 2007-02-15
AU2005264063B2 (en) 2009-09-10
NZ552091A (en) 2009-09-25
EP2322217A3 (en) 2011-09-28
TWI309167B (en) 2009-05-01
BRPI0513200A (en) 2008-04-29
AR049985A1 (en) 2006-09-20
EP2335727A2 (en) 2011-06-22
NO20070702L (en) 2007-03-29
EP2322215A3 (en) 2011-09-28
AU2005264063A1 (en) 2006-01-26
US20110014207A1 (en) 2011-01-20
KR20080019733A (en) 2008-03-04
RU2007101387A (en) 2008-07-20
TW200812621A (en) 2008-03-16
EP2322217A2 (en) 2011-05-18
US7618626B2 (en) 2009-11-17
IL210401A0 (en) 2011-03-31
IL180422A0 (en) 2008-03-20
AU2009210360A1 (en) 2009-09-10
JP2008506681A (en) 2008-03-06
EP2322215A2 (en) 2011-05-18
CN101014365B (en) 2011-04-13
EP2335727A3 (en) 2011-09-28
IL210399A0 (en) 2011-03-31
CA2573821A1 (en) 2006-01-26
US20060018910A1 (en) 2006-01-26
MX2007000610A (en) 2007-03-07
IL210400A0 (en) 2011-03-31

Similar Documents

Publication Publication Date Title
US7618626B2 (en) Combination treatment for non-hematologic malignancies
EP1819735A1 (en) Ctla-4 antibody and aromatase inhibitor or combination treatment for breast cancer
AU2004212344B2 (en) Uses of anti-insulin-like growth factor I receptor antibodies
EP3347054B1 (en) Dosing regimens for anti-tf-antibody drug-conjugates
TW200840583A (en) Methods of treatment
CN102812045A (en) Material And Methods For Treating Or Preventing HER-3 Associated Diseases
KR20230098279A (en) Combinations of PDX inhibitors or doxorubicin with AHR inhibitors
CN111148534A (en) anti-IGF and anti-PD-1 anti-cancer combination therapy
US20240317854A1 (en) Methods for treating cancer with anti-ilt3 antibodies
KR102239752B1 (en) Pharmaceutical composition for preventing or treating cancer comprising PD-L1 antibody and cancer-specific prodrug nanocomplex
JP2023531090A (en) drugs to treat tumors
JP2024527974A (en) Drug combinations to treat small cell lung cancer
WO2021088853A1 (en) Drug combination of quinoline derivative and pd-1 monoclonal antibody

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/000610

Country of ref document: MX

AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 552091

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2005264063

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 180422

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 06130676

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: 12007500077

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 200700385

Country of ref document: ZA

Ref document number: 2573821

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1020077001027

Country of ref document: KR

Ref document number: 2007101387

Country of ref document: RU

WWE Wipo information: entry into national phase

Ref document number: 2007520919

Country of ref document: JP

Ref document number: 200580024027.3

Country of ref document: CN

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 449/DELNP/2007

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2005264063

Country of ref document: AU

Date of ref document: 20050704

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005264063

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2005757374

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020077001027

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2005757374

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0513200

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: 210400

Country of ref document: IL

Ref document number: 210399

Country of ref document: IL

Ref document number: 210401

Country of ref document: IL